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Abstract 
Jingliang Yan 
ROLE OF RAP1 IN ANGIOGENESIS AND TUMOR INVASION 
Rap1a and Rap1b are two closely related members of the Ras family of 
small GTPase. Despite their high sequence similarity, the two proteins serve non-
redundant functions in cells and organs. Rap1a plays critical roles during mouse 
development, and both Rap1a and Rap1b are required for angiogenesis. In 
glioblastoma cells, however, Rap1b plays a more unique role in tumor cell 
invasion. 
Loss of rap1a in mice resulted in 40% embryonic lethality, and caused 
cardiac defects in mouse embryos and cardiac hypertrophy in adult mice. These 
phenotypes, distinct from those of the rap1b knockout mice, suggest differential 
roles of the two GTPases during mouse development. 
Angiogenesis, the formation of new blood vessels by endothelial cells, is 
impaired by the loss of rap1. Blood vessel growth into FGF2-containing Matrigel 
plugs was absent from rap1a-/- mice and aortic rings derived from rap1a-/- mice 
failed to sprout primitive endothelial tubes in response to FGF2 when embedded 
in Matrigel. Knocking down either rap1a or rap1b in human micro-vascular 
endothelial cells (HMVECs) confirmed that Rap1 plays key roles in endothelial 
cell function. The knockdown of rap1a or 1b resulted in decreased adhesion to 
extracellular matrices and impaired cell migration. Rap1 deficient endothelial cells 
failed to form 3-D tubular structures when plated on Matrigel in vitro. The 
vii 
activation of ERK, p38, and Rac, important signaling molecules in angiogenesis, 
were all reduced in response to FGF2 when either Rap1 protein was depleted. 
In U373 human glioblastoma multiform cells, depletion of rap1b, but not 
rap1a drastically reduced tumor cell invasion by decreasing the activity of 
secreted matrix metalloproteinase 2 (MMP2). The adhesion of cells to the 
extracellular matrices collagen or fibronectin, but not to vitronectin, was 
decreased upon rap1b depletion. However, a mild increase in proliferation 
associated with elevation in ERK1/2, p38, Akt and ribosomal S6 protein activation 
was observed in cells depleted of either rap1a or rap1b. When an MEK1/2 
inhibitor U0126 was used, the phosphorylation of p38, Akt and S6 were 
decreased, however, to various levels, suggesting complex regulatory pathways 
mediate Rap1 action in glioblastoma cells. 
 
Lawrence A. Quilliam, Ph.D., Chair 
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INTRODUCTION 
1. Ras family of small GTPases 
The Ras family of GTPases are G proteins with molecular weights of 
20~25 kDa. They cycle between GDP-bound inactive and GTP-bound active 
forms. In their resting state, these small GTPases are associated with GDP. 
Upon cellular stimulation, guanine-nucleotide exchange factors (GEFs) replace 
the GDP with GTP, triggering a conformational change in the switch 1 and switch 
2 domains of Ras proteins. This allows for the binding and subsequent activation 
of downstream effectors. Once the signal is transduced, the bound GTP is rapidly 
hydrolyzed back to GDP with the help of GTPase activating proteins (GAPs), as 
the intrinsic GTPase activity of Ras proteins is very weak (1). Due to this unique 
cycling, these small GTPases serve as molecular switches in the cell and are 
central hubs of signal transduction, governing a myriad of cellular functions 
ranging from cell proliferation, differentiation, apoptosis, to cell adhesion, 
migration and morphological changes. Aberrant Ras protein activities are present 
in a variety of diseases, including cancer (2) and cardiovascular diseases (3), 
and therefore, the study of the role of each Ras protein in different cell types and 
disease settings will greatly aid us in the understanding of the biology, the 
pathogenesis and the therapeutic treatment. 
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1.1. Rap1 small GTPase 
Rap1 is the most related GTPase to Ras with about 50% sequence 
identity (4). It has a virtually identical effector binding domain to Ras, thus can 
bind to many of the same effectors. Historically, Rap1 was independently 
discovered as a Ras related cDNA (Ras proximate) (4) and as K-rev1 (Ki-Ras 
revertant) to be able to reverse the Ras transformation in fibroblasts (5). It binds 
tightly to c-Raf-1, a Ras effector, but lacks the ability to activate it, therefore 
depleting the available pool of Raf-1 for Ras (6). Later research revealed that 
Rap1 can activate B-Raf to promote MAPK activation and mimic the effect of Ras  
(7). To date, after extensive studies, many important cellular processes have 
been accredited to the indispensable functions of Rap1, and it therefore has 
emerged as a critical cellular signaling mediator. Rap1 has been shown to 
activate Akt through PI3K in thyroid cells, B and T cells (8-12); to regulate Rac 
activity and cytoskeletal structures (13); and to promote integrin activation via an 
“inside-out” signaling mechanism in almost all cell types (14). Rap1 has been 
found in the Golgi (15), lysosomal vesicles (16), perinuclear structures (17), 
nucleus (18, 19), endosomes (20), the plasma membrane (21), and epithelial 
cell-cell junctions (22). This widespread distribution of Rap1 in part dictates its 
diverse functions in the cell. 
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1.2. Rap1a and Rap1b 
The Rap1 family consists of two proteins, Rap1a and Rap1b. They share 
95% sequence identity, but are encoded by different genes (23). The main 
difference lies in their C-termini (Figure 1). Whether or not these two family 
members serve redundant or distinct functions is still in debate. Both rap1a and 
rap1b knockout mice suffer only partial lethality (~40% for rap1a-/- and ~85% for 
rap1b-/-), suggesting they could partially compensate for the loss of each other. 
The attempt to create rap1a and rap1b double knockout mice also failed. On the 
other hand, the rap1a-/- mice had defective myeloid cell functions not seen in the 
rap1b null mice (24), and the rap1b knockout mice have a unique bleeding 
disorder due to platelet defect (25), pointing to the distinctive responsibilities 
Rap1a and 1b may carry. At the cellular level, in epithelial cells, Rap1a and 1b  
 
Rap1a  MREYKLVVLGSGGVGKSALTVQFVQGIFVEKYDPTIEDSYRKQVEV 46 
Rap1b  MREYKLVVLGSGGVGKSALTVQFVQGIFVEKYDPTIEDSYRKQVEV 46 
 
Rap1a  DCQQCMLEILDTAGTEQFTAMRDLYMKNGQGFALVYSITAQSTFND 92 
Rap1b  DAQQCMLEILDTAGTEQFTAMRDLYMKNGQGFALVYSITAQSTFND 92 
 
Rap1a  LQDLREQILRVKDTEDVPMILVGNKCDLEDERVVGKEQGQNLARQW 138 
Rap1b  LQDLREQILRVKDTDDVPMILVGNKCDLEDERVVGKEQGQNLARQW 138 
 
Rap1a  CNCAFLESSAKSKINVNEIFYDLVRQINRKTPVEKKKPKKKSCLLL 184 
Rap1b  NNCAFLESSAKSKINVNEIFYDLVRQINRKTPVPGKARKKSSCQLL 184 
 
Figure 1. Sequence alignment of Rap1a and Rap1b proteins. 
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also seem to perform different roles. Both Rap1a and Rap1b participate in 
epithelial cell junction formation, however, Rap1a is required for junction 
maturation while Rap1b controls the expression of E-cadherin (26). During cell 
migration, Rap1a but not Rap1b depletion resulted in decreased ?1 integrin 
production and reduced cell migration (27). These data suggest that the two 
closely related Rap1 family members have individual functions, but could also be 
due to differential expression profiles in various cell types. 
 
1.3. Downstream pathways of Rap1 signaling 
GTP loaded Rap1 activates many signaling pathways through its effectors, 
which include PLC, PI3K, Raf, Ral-GDS, RAPL and Riam. These effectors can 
then propagate signals to regulate: Raf/ERK pathway which modulates a wide 
array of cellular functions; RAPL and Riam which promote integrin activation, cell 
adhesion and migration; and another small GTPase Rac which controls actin 
cytoskeleton rearrangement and cell morphology. 
 
1.3.1. Mitogen activated protein kinase (MAPK) 
Mitogen activated protein kinases (MAPKs) are important signaling 
molecules in cells that transduce signals from the extracellular environment. 
These proteins include extracellular signal regulated kinase (ERK), p38 and c-jun 
N-terminal kinase (JNK). The MAP kinase signaling cascades are characterized 
by their linear activation. They are activated by phosphorylations on conserved 
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Ser/Tyr residues by specific MAP kinase kinases (MAPKKs or MEKs). MAPKKs 
are also regulated in such a way by MAP kinase kinase kinases (MAPKKKs) 
(28). The most extensively researched MAPK are ERK1/2 (p44/p42) that are 
activated by a Raf-MEK-ERK cascade. Upon its activation, it can regulate a wide 
variety of cellular functions, including survival, proliferation, protein expression, 
cell cycle control, and migration (29). 
As discussed earlier, the first linkage between Rap1 and MAPKs was 
established upon the discovery of Rap1. It can bind with high affinity to Raf-1, a 
MEKK for ERK, but not activate it. But later research revealed that in cell types 
that express B-Raf, Rap1 could also activate ERK and lead to various cellular 
outcomes. For instance, in megakaryocytes, Rap1 drives a sustained ERK 
activation, which is required for differentiation (30, 31). In astrocytes, Rap1 also 
induced ERK phosphorylation in response to thrombin stimulation to promote 
proliferation (32). 
Besides ERK, another MAPK p38 has also been shown to be regulated by 
Rap1. Originally named SAPK (stress activated protein kinase), p38 mostly 
imposes negative regulation on cell proliferation and survival, and maintains 
homeostasis (33). In certain cases, activation of Rap1 could lead to p38 
phosphorylation, and can exert growth inhibitory and pro-apoptotic effects (34), 
regulates neuronal synaptic plasticity (35, 36), or modulates muscle cell 
stretching (37). 
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1.3.2. RAPL and integrins 
Integrins are cell-surface receptors that bind extracellular matrix proteins, 
and are involved in cell adhesion, migration, and basement membrane 
rearrangements (38). They are composed of ? and ? subunits that are non-
covalently associated together. Upon stimulation, intracellular signals direct the 
assembly of a protein complex at the cytoplasmic tail of integrins, which then 
promotes the extension of integrins to their active conformations. Since the 
information comes from inside the cell, this process is often referred to as “inside-
out” signaling. 
Once integrins make contact with extracellular matrix proteins, to bind 
tightly with the ECM, the cell also has to respond to the initial attachment. The 
cytoplasmic portions of integrins will need to cluster together, and anchor onto 
the cytoskeleton. This structure is known as the focal adhesion (39). Therefore, 
integrin signaling is bidirectional, both from inside-out and from outside-in. This 
process is likely to involve the regulation by many different proteins. 
Rap1 has been implicated as a major regulator of integrin activation 
through its downstream effectors, Riam and/or RAPL. Overexpression of Riam in 
T cells led to ?1 and ?2 integrins activation, the same effect as the expression of 
constitutively active Rap1 (40). The activation of platelet integrins, ?IIb?3, also 
requires the presence of Riam (41). Another Rap1 effector, RAPL, is required for 
LFA binding to ICAM-1 in lymphocytes (42). It also colocalizes with active Rap1 
to the leading edge of migrating endothelial cells (43). 
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1.3.3. Rac small GTPase 
The Rho family small GTPases RhoA, Rac and CDC42 are important 
regulators of cytoskeletal structures. RhoA induces stress fiber formation, Rac 
modulates lamellipodium extension and actin polymerization, and CDC42 
regulates filopodium formation and cell polarity (44). Rac plays important roles in 
the regulation of actin dynamics through its effector PAK (p21 activating kinase) 
during cytoskeletal rearrangements, formation of membrane ruffles and 
lamellipodia, and phagocytosis. MEFs that are deficient in Rac1 exhibited loss of 
actin stress fibers and lamellipodia formation, as well as reduced focal adhesion 
foci (45). In yeast, the Rap1 homolog, Bud1p/RSR couples CDC24 to the site of 
bud formation (46, 47). CDC24 is a GEF for the Rho family protein CDC42, and 
this provided the first evidence that Rho GTPases are under the regulation of 
Rap1. In eukaryotic cells, Rap1 has been shown to regulate Rac activity through 
binding and distribution of Rac GEFs Vav2 and Tiam1 to the sites of Rac 
activation, similar to the regulation of CDC24 in yeast. Overexpression of Vav2 
and Tiam1 activates Rac independently of Rap1, but in order to promote cell 
spreading, the redistribution of Vav2 and Tiam1 to the cell edge by Rap1 is 
required. In migrating cells, active Rap1, Vav2, Rac and PAK have been shown 
to co-localize at the peripheral ruffles (13). These data suggest that through the 
subcellular localization of Rac GEFs, Rap1 can also modulate Rac activity and 
cell morphological changes. 
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1.4. Rap1 GEFs and cell surface receptors 
Rap1 is activated by many extracellular ligands that bind to cell surface 
receptors, such as receptor tyrosine kinases (RTKs) and G protein-coupled 
receptors (GPCRs). The activated receptors then signal to Rap1 GEFs to replace 
the GDP on Rap1 with GTP, and activate Rap1. To date, five different groups of 
Rap1 GEFs have been discovered, and they activate Rap1 in response to a 
variety of cellular stimulations. SmgGDS was the first Rap1 GEF found (48), but 
whether it is a true GEF for Rap1 is still controversial. It works on Rap1 as well as 
K-Ras and Rho family GTPases, and catalyzes GDP/GTP exchange better on 
the Rho GTPases than on Rap1 (49, 50). The next Rap1 GEF identified was C3G 
(Crk SH3 binding GEF). It is recruited to the receptor- or non-receptor tyrosine 
kinases by binding of a proline rich region (usually XPPXP, where X is an 
aliphatic residue) to the SH3 domain of the Crk or Crkl adaptor proteins. C3G is 
ubiquitously expressed and serves fundamental role in cells, as knockout mice 
died early during embryonic development at 7.5 days (51). A C3G hypomorphic 
mutant revealed defects in blood vessel maturation and cerebral cortex 
development (52, 53). MEFs lacking C3G exhibited increased random motility 
and decreased adhesion on extracellular matrix (51), suggesting the C3G-Rap1 
axis is important for integrin-dependent cell adhesion and migration. 
Another group of Rap1 GEFs, RasGRPs (or CalDAG-GEFs), are activated 
by intracellular second messenger DAG and/or Calcium owing to their C1 and C2 
domains similar to protein kinase C, and their “EF hands” homologous to those in 
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calmodulin (54). Of the four GRPs, GRP2 can activate Rap1 (55, 56) whereas 
RasGRP3 has the ability to regulate a variety of GTPases including Rap1 and 2 
(57, 58). They can be activated downstream of PLC which cleaves PIP2 to 
produce IP3 and DAG. 
Around the same time, a novel group of Rap1 GEFs, Epac1 and 2 
(exchange proteins directly activated by cyclic AMP), was discovered (59, 60). 
They have a cAMP-binding domain very similar to the cAMP-binding site on PKA 
that also serves an auto-inhibitory function on the GEF activity in the absence of 
cAMP (61). Epac1 is widely expressed (60, 61), while Epac2 is highly enriched in 
the brain and adrenal glands (60). Their discovery unraveled the effect of cellular 
cAMP on Rap1 activation not explained by PKA function, such as insulin 
secretion and some signaling events downstream of G protein-coupled receptors 
(62-66). In addition, it provides a means to directly activate Rap1 without 
affecting PKA by using a cAMP analog 8Cpt-cAMP, which specifically binds to 
Epac (67). The regulation of Rap1 activity through Epac, however, does not rely 
solely on cAMP binding. Epac2 contains a RA (Ras association) domain that can 
bind GTP-loaded Ras. Upon this binding, Epac2 is translocated to the plasma 
membrane where it activates a specific pool of Rap1. This subcellular 
compartmentalization can be mimicked by artificially adding a membrane 
targeting C-terminal CAAX sequence to Epac2 protein (68, 69). 
Similarly regulated by Ras-GTP, and also structurally related to Epacs are 
the MR-GEF and PDZ-GEFs. However, despite being closely related to Epac2, 
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MR-GEF does not have the cAMP-binding domain, but is regulated by M-Ras-
GTP binding to its RA domain (57). PDZ-GEFs retain cAMP-binding like 
domains, but lack the key residues required for cyclic nucleotide binding. Instead, 
they have PDZ domains that may localize the GEFs to various subcellular locales 
such as GPCRs (70) and cell junction proteins (22, 71). 
The Rap1 GEFs work in accordance with signals from extracellular stimuli, 
such as growth factors or cytokines. Upon ligand binding, cell surface receptors 
promote local Rap1 activation through the recruitment and activation of various 
Rap1 GEFs. For example, in 3T3 cells, PDGF binding to PDGFR triggers the 
autophosphorylation of tyrosine residues on PDGF receptors, which provides the 
binding sites of adaptor proteins such as Crk. Crk, in turn, brings C3G to the 
proximal site and activate the pool of Rap1 located at the leading edge of a 
migrating cell (72). Simultaneously, tyrosine phosphorylated PDGF receptors can 
also activate PLC through direct binding, and PLC catalyzes the cleavage of 
membrane-bound PIP2 to produce DAG and activates Rap1. This provides a 
paradigm of spatial and temporal regulation of Rap1 in response to extracellular 
signal stimulation. 
 
2. Angiogenesis 
Angiogenesis is the formation of new vessels from pre-existing capillaries 
by endothelial cells. It is an essential process both during development and 
throughout life. Deficient angiogenesis could lead to ischemia and various 
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cardiovascular diseases, and excessive angiogenesis is often exploited by 
tumors to support their unrestrained growth. 
 
2.1. Endothelial cells 
Endothelial cells are the building blocks of blood vessels. The endothelial 
monolayer constitutes the basic structure of all vessels, from a capillary to an 
artery, and forms a barrier to prevent the leakage of blood and plasma. 
Therefore, their regulation is of crucial importance to the homeostasis of the 
vascular system. Endothelial cells are characterized by their surface expression 
of various markers, such as PECAM (CD31), vWF, VEGFR-1 (Flt-1) and VE-
Cadherin (CD144) (73). The endothelial monolayer is more permeable than the 
epithelial monolayer, which fulfills the role of oxygen, nutrient, and waste 
exchange. As a result, endothelial cell-cell contacts are enriched in adherens 
junctions (AJs) that are mediated by homophilic ligation of VE-Cadherin, and 
have fewer tight junctions (74). Many cell types, including pericytes, 
macrophages and progenitor cells, contribute to this process, however, the 
regulation of endothelial cells by growth factor forms the basis of all angiogenic 
manipulation. The angiogenic process is usually initiated by increased vascular 
permeability. Metalloproteinases (MMPs) are secreted to break down basement 
membrane proteins and make way for endothelial cell movement. Accompanying 
this is increased endothelial cell proliferation. Endothelial cells then sprout from 
the existing vessel and migrate toward the site of needed blood perfusion. The 
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last step is for the endothelial cells to reestablish connection with each other, 
form tubuler structures and finally mature into new capillaries (75). 
 
2.2. Growth factor regulation of endothelial cell functions during 
angiogenesis 
The original and most classic growth factor that stimulates angiogenesis is 
vascular endothelial growth factor (VEGF). It was first identified to cause vessel 
leakage, and was thus initially called vascular permeability factor (76, 77). Now, 
VEGF has received enormous attention for its pro-angiogenic effects on 
endothelial cells. It is required during embryogenesis, as well as for postnatal 
development. VEGF signaling promotes endothelial cell proliferation, protects 
them from apoptosis, and guides endothelial morphogenesis during vessel 
maturation (78). 
Besides VEGF, another broadly studied family of pro-angiogenic factors 
are the fibroblast growth factors (FGFs). They are heparin-binding growth factors 
that interact with cell surface receptor tyrosine kinases (RTKs), heparan-sulfate 
proteoglycans (HSPGs) and intergrins. FGFs were among the first identified 
growth factors that have angiogenesis-stimulating effects on endothelial cells (79, 
80). Of the 22 members of the FGF family, FGF1 and 2 (or acidic and basic 
FGFs, respectively) have been intensely studied. They exert their biological 
activities by binding to cell surface RTKs fibroblast growth factor receptors 
(FGFRs), and induce their autophosphorylation. FGFRs have far fewer 
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phosphotyrosine residues compared to other RTKs, and the docking protein, 
FGF receptor substrate (FRS), is the main mediator of FGFR signaling in cells. 
FRS binds to FGFR constitutively, and is rapidly phosphorylated upon FGF 
stimulation. The tyrosin-phosphorylated FRS then functions as a docking site for 
protein complexes such as Grb2/Sos to bind and activate downstream Ras 
signaling (81). Among the few tyrosine residues on FGFR, pY766 has been 
proven to be the binding site for PLC? and adaptor protein Shb (82, 83). Shb 
contributes to FRS mediated Ras/MAPK pathway activation, while PLC? could 
generate intracellular second messengers IP3 and DAG. FGF can stimulate 
endothelial cell proliferation by activating MAPK signaling pathway (84), enhance 
extracellular matrix degradation by upregulating uPA and MMP expression (85, 
86), regulate endothelial cell adhesion and migration (87), and guide endothelial 
tube morphogenesis (88). More recently, FGF has also been found to induce 
VEGF production in endothelial cells, and promote angiogenesis by modulate the 
VEGF/VEGFR system (89). 
 
2.3. Rap1 and endothelial cells 
Several lines of evidence have pointed to the important role of Rap1 in 
regulating endothelial cell functions. Rap1 could mediate angiotensin II induced 
Pyk2 phosphorylation (90); in migrating cells, Rap1 activation promotes focal 
complex stabilization, and localizes to the leading edge of cell migration, along 
with its effector RAPL (43). Rap1 also regulates homotypic interaction between 
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VE-cadherins in endothelial cells as it similarly regulates E-cadherin binding in 
epithelial cells. Activation of Rap1 in endothelial cells promotes VE-cadherin 
engagement between adjacent cells, and therefore tightens cell-cell junction and 
decreases vascular permeability (91-94). TIMP2 through Rap1 activation 
promotes cell spreading and inhibits endothelial cell migration by decreasing 
MMP production (95). To date, the regulation of Rap1 in endothelial cells are 
mediated by Crk, which could recruit C3G, or alternatively by activating Epac. 
However, we cannot rule out the possibility that other Rap1 GEFs participate 
through parallel pathways. 
 
3. Rap1 and tumors 
Given the important roles Rap1 plays in growth, morphology and cell 
migration in a wide spectrum of cell types, it is not surprising to see altered Rap1 
activity present in various tumors. Most commonly this has been attributed to the 
loss of function or reduced expression of Rap1 GAPs, which results in elevated 
Rap1 activity. However, discrepancies remain in whether Rap1 deserves a “bad 
Rap” in cancer progression. 
 
3.1. Rap1 and tumorigenesis 
Numerous reports have implied that Rap1 activation contributes to the 
tumorigenic process, and that higher Rap1-GTP levels are often observed in 
tumor samples. For example, elevated Rap1-GTP level could be detected in 
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several human melanoma samples, and were associated with HGF induced ERK 
activation (96). The same group later discovered that Rap1-GAP expression was 
down-regulated due to promoter hypermethylation (97). This represents a 
common scenario of how tumors manipulate Rap1 activity. Besides melanomas, 
the loss of Rap1GAP has also been observed in cervical cancers (98), papillary 
thyroid cancers (99), squamous cell carcinoma (100), and pancreatic cancer 
(101). 
In addition to the classical Rap1GAP, there are numerous other Rap 
GAPs that include Spa-1, E6TP1, KIAA1389, and CAPRI. The loss of some of 
these Rap GAPs has also been reported in cancer. In particular, Spa-1 (or Sipa), 
has become the focus in myeloid leukemia research, and may shed light on the 
mechanisms of malignant transformation of tumors. Spa-1 is the major Rap1 
GAP expressed in hematopoietic cells, and its whole body knockout in mice 
resulted in myeloproliferative disorders resembling human chronic myeloid 
leukemia (hCML) in most mice, albeit after a long latent period (102). These 
reports collectively suggest that Rap1, although not as strong an oncogene as 
Ras, plays an important role in the tumorigenic process. 
 
3.2. Rap1 and tumor invasion and metastasis 
The role of Rap1 in tumor metastasis, however, points in a different 
direction, suggesting Rap1 being a gatekeeper for metastasis. Despite the 
leukemogenic tendency in spa1-/- mice, the expression of Spa-1 in other cancer 
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types has been associated with higher grade of tumor metastasis. 
Overexpression of wild type Spa-1 in mammary tumor cells drastically increased 
their metastasis to lung, and in accordance, the silencing of spa1 reduced such 
activity (103). Higher Spa-1 expression level also correlates with a higher 
metastatic potential in prostate cancer cell lines (103). On the other hand, in 
metastatic melanoma cells, activation of Rap1 induced ?V?3 integrin activation 
and enhanced tumor cell migration (96). These confounding observations warrant 
further dissection of the precise roles of Rap1 in different cancer types. 
 
3.3. Rap1 and brain tumors 
3.3.1. Brain tumor overview 
Although brain tumors represent only approximately 2% of all cancers, 
they are the fourth leading cause of all cancer-related deaths. Tumors originated 
from glial cells (astrocytomas and ependymomas) are generally more common 
than tumors from oligodendrocytes (oligodentrogliomas). Ependymomas and 
oligodentrogliomas are slow-growing tumors, usually with defined boundaries, 
although they also can be malignant. Low-grade astrocytomas, such as pilocytic 
astrocytoma, are slow-growing benign tumors most often seen in children and 
young adults. On the other hand, high-grade astrocytomas grow rapidly, and 
predominate in older patients (104). Glioblastoma multiforme (GBM) is the most 
frequent and malignant form of astrocytoma (grade IV, the highest grade). 
Patients suffer from a poor prognosis with fewer than 3% surviving longer than 
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five years after initial diagnosis (105). Glioblastomas are highly proliferative, 
highly angiogenic and highly invasive, although they are rarely metastatic. The 
most commonly occurring defects associated with glioblastoma are loss of 
heterozygosity at chromosome 10q (LOH 10q), epidermal growth factor receptor 
(EGFR) amplification, PTEN mutation and p53 mutation (106). EGF and RTK 
signaling play important roles during CNS development (107), and the 
overexpression of EGFR, or the expression of its truncated form, EGFRvIII, is 
commonly seen in glioblastomas (108). These tumors are hypersensitive to EGF 
stimulation, or activated independent of EGF binding. The result is constitutively 
activated EGFR, leading to downstream signaling pathways such as 
Sos/Ras/ERK and PI3K/Akt/mTOR to promote cell proliferation, survival and 
invasion. The tumor suppressor gene pten is also frequently mutated in 
glioblastomas (109, 110). PTEN is a tyrosine and lipid phosphatase that can 
dephosphorylate PIP3, and antagonizes the PI3K/Akt pathway. Loss of PTEN 
function therefore also contributes to the augmentation of survival pathways 
activated by Akt. 
 
3.3.2. Rap1 and glioblastoma 
In searching for additional causes of glioblastoma and a therapeutic target, 
Rap1 emerged as a possible candidate. Analysis of sporadic astrocytomas 
revealed overexpression of Rap1 in ~50% of tumor samples (111). In addition to 
protein level, increased Rap1 activity has also been associated with malignant 
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gliomas. Using gene array, a decrease in Rap1GAP expression has been found 
in mouse glioblastomas (112). The loss of Rap1 GAP expression may explain the 
elevated Rap1 activity in human glioblastoma multiforme (GBM) tumors (113). 
19 
RESEARCH OBJECTIVES 
The three parts of this study are centered with the functions of the small 
GTPase Rap1, or to be more precisely, Rap1a and Rap1b, in cells and animals. 
The long-term goal is to better understand the role Rap1 plays in normal and 
diseased settings, and to validate the use of rap1a knockout mouse as an animal 
model for the study of various diseases. Three specific aims were addressed to 
achieve this task. 
Aim 1, to further characterize the rap1a knockout mouse. Examination of 
embryos from the rap1a null mouse revealed embryonic edema as well as 
multiple developmental cardiac defects. Adult rap1a-/- mice also suffered from 
cardiomegaly. These data suggest that the Rap1a protein plays important roles 
during mouse development. 
Aim 2, to elucidate the regulation of endothelial cells during angiogenesis 
by Rap1. The rap1a knockout mouse had a defective angiogenic response to 
FGF2 stimulation. Human microvascular endothelial cells (HMVECs) depleted of 
either rap1a or rap1b exhibited impaired cellular functions and abrogated 
intracellular signal transduction, placing Rap1 centrally in the modulation of 
endothelial cell functions. The accomplishment of this aim also validates the 
rap1a null mouse as a viable animal model to study angiogenesis-related 
diseases in a more physiological condition. 
Aim 3, to explore how Rap1 activity may affect glioblastoma multiform 
malignancy. U373MG glioblastoma cells depleted of rap1b showed drastically 
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decreased invasion, associated with reduced MMP2 and integrin activities. These 
cells, however, had elevated ERK1/2, Akt, and p38 phosphorylation levels, 
suggesting that Rap1 may play two distinct roles in glioblastoma cells. 
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MATERIALS AND METHODS 
1. Animals 
rap1a-/- mice were generated as previously described (114) and 
backcrossed into C57BL6 background for 11 generations. Experiments were 
carried out in accordance with an Indiana University Institutional Animal Care and 
Use Committee approved protocol. 
 
2. In vivo Matrigel plug assay 
Matrigel (BD Biosciences, San Jose, CA, USA) was thawed and kept on 
ice. For assays with VEGF, the Matrigel was mixed with PBS ± 600 or 150 ng/mL 
VEGF-A165 (Peprotech, Rocky Hill, NJ, USA). For assays with FGF2, the 
Matrigel was mixed with PBS and 60 U/mL Heparin (Sigma-Aldrich, St. Louis, 
MO, USA) ± 600 ng/mL FGF2 (Peprotech). 400 μL Matrigel was subcutaneously 
injected into the mouse groin area using a 27G needle. During injection, the 
needle was moved slightly from side to side to create a pouch for the gel to form. 
Caution was taken not to damage any major vessels. After 7 days, plugs were 
harvested, photographed, and assayed for total hemoglobin using a hemoglobin 
reagent kit (Pointe Scientific, Lincoln Park, MI, USA) according to the 
manufacturer?s instructions. Additional plugs were fixed in IHC Zinc fixative (BD 
Biosciences) for 36 hours at room temperature and embedded in paraffin. Serial 
5 μm cross-sections were made at 100 μm intervals across the length of the 
Matrigel plug. For immuno-staining, sections were blocked for endogenous 
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peroxidase activity with 3% hydrogen peroxide in methanol following antigen 
retrieval in Antigen Unmasking Solution (Vector Laboratories, Burlingame, CA, 
USA) at 95oC. Sections were blocked in 3% bovine serum albumin (BSA; Sigma-
Aldrich, St. Louis, MO, USA) for 1 hour and were stained for CD31 (anti-CD31, 
1:50; BD Pharmingen, San Jose, CA, USA). Purified class- and species-matched 
immunoglobulins (BD Pharmingen) were used for isotype controls. Sections were 
incubated with biotinylated anti-rat IgG (Vector Laboratories) followed by 
incubation with streptavidin-cy3 (Molecular Probes, Invitrogen, Carlsbad, CA, 
USA). The slides were mounted in 90% glycerol/10% PBS, pH 8.0, containing 6-
diamidino-2-phenylindole dihydrochloride (DAPI; Sigma) to permit nuclear 
identification. Sections were examined and images of sections were collected 
using a Zeiss Axioskop microscope (Carl Zeiss, Chester, VA, USA) with a 20X 
CP-ACHROMAT/0.12NA objective and a SPOT RT color camera (Diagnostic 
Instruments, Sterling Heights, MI, USA).    
 
3. Ex vivo mouse aortic ring assay 
Mouse aortas were freshly dissected and placed in ice-cold ?-MEM. Fatty 
tissues surrounding the aorta were cleaned under a dissecting microscope. 
Caution was taken not to clamp the aorta firmly to prevent damaging the 
endothelial cells from tube sprouting. The cleaned aortas were rinsed in cold ?-
MEM 3 times to remove residual blood before being sliced into 1 mm thick rings 
using a surgical scalpel. The rings were further washed before embedding 
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between two layers of 50 μL growth factor reduced Matrigel (BD Biosciences) 
supplemented with 20 U/mL heparin. The Matrigel was overlaid with 100 μL 
EBM-2 basal medium (Lonza, Walkersville, MD, USA) with 2% fetal bovine 
serum (FBS; Atlanta Biologicals, Lawrenceville, GA, USA) plus 25 ng/mL FGF2 
or PBS and cultured in 37oC, 5% CO2 humidified incubator for 7 days with 
medium change every 3 days. The outgrowth and branching of endothelial tubes 
was counted under a Nikon Diaphot 300 inverted microscope at 100x magnitude 
and photographed using an attached Nikon Coolpix 995 camera. 
 
4. Generation of Rap1b anti-serum 
Rabbit anti-serum against human Rap1b protein was raised against 
peptide sequence TPVPGKARKKSS conjugated to keyhole limpet hemocyanin 
(QCB, Hopkinton, MA, USA). The anti-serum was tested with Rap1a or 1b null 
MEFs or 293T cells expressing either HA-Rap1a or 1b. 
 
5. Cell culture 
Human micro-vascular endothelial cells (HMVECs) (Lonza) were 
maintained in EGM-2 mv complete micro-vascular endothelial cell growth 
medium (Lonza). Human glioblastoma multiform cell line U373-MG was 
maintained in RPMI-1640 supplemented with 10% fetal bovine serum and 
penicillin/streptomycin. 293T cells were maintained in DMEM (Lonza) 
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supplemented with 10% FBS and penicillin/streptomycin. All cells were cultured 
in a humidified 37oC, 5% CO2 incubator. 
 
6. Generation and immortalization of mouse embryonic fibroblasts 
Freshly dissected mouse embryos of 14.5 embryonic days were washed 
twice in sterile PBS. The head portion of the embryo was removed by forceps. 
Caution was taken not to cross contaminate cells from different embryos. The 
remaining body of the embryo, together with 800 μL DMEM was passed through 
a 1 mL syringe with a 21 G needle three times before plating on a tissue culture 
dish with DMEM plus 20% FBS. The following day, medium was changed to 
remove non-attached cells. Isolated fibroblasts were cultured for additional 7 
days in DMEM plus 15% FBS, with medium change every two days. 
For immortalization of MEFs, retroviral supernatant from Psi-2 packaging 
cell line stably expressing simian virus 40 (SV40) large T antigen was collected 
and overlaid on freshly generated MEFs. Virus-infected MEFs were cultured for 
two weeks until non-infected cells senesced. The immortalized cells were then 
subjected to assays, or frozen with DMEM supplemented with 25% FBS and 10% 
DMSO. 
 
7. Isolation of mouse macrophages 
Wild type or rap1a knockout mice of 1 to 3 months old were sacrificed, and 
the tibias and iliac crests were isolated. The bones were cleaned of muscles, and 
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washed in sterile IMDM once. Each bone was cut open at both ends, and the 
bone marrow was flushed out using a 20 mL syringe with a 23 G needle. 
Following centrifugation at 1500 rpm for 5 minutes, the cells were resuspended in 
5 mL IMDM, and added slowly to 5 mL Ficol (Sigma). After gradient 
centrifugation at 1500 rpm for 30 minutes with no braking force, the middle phase 
was collected, reconstituted to 40 mL, and centrifuged at 1500 rpm for 5 minutes. 
The pellet was then resuspended in 10 mL IMDM supplemented with 20% FBS 
and 50 ng/mL M-CSF (Peprotech), and plated on non-tissue culture treated petri-
dishes. The following day, non-adherent cells were transferred to a new dish, and 
cultured for another 7 days in IMDM supplemented with 20% FBS and 50 ng/mL 
M-CSF. 
 
8. Digestion of mouse digits and genotyping by PCR 
Mice genotyping was performed as previously described (114). Briefly, 
digits from newborn mice of 8 to 12 days were cut and digested overnight at 55oC 
in the digestion solution (1x PCR buffer without Mg2+, 0.005% SDS, 20 mM DTT, 
and 50 ng/μL proteinase K). Proteinase K was denatured by incubating samples 
at 90oC for 30 minutes. Samples were cooled down to room temperature, and 
centrifuged at 13,000 rpm for 10 minutes. One μL of the supernatant was used 
as the template for PCR. Three primers, 0.3 μM common primer Rap1A 5?KO, 
0.05 μM Neo specific primer ADPR266, and 0.25 μM wild type specific primer 
RapExon, were used in a single reaction. The reaction condition was as follows: 
26 
93oC for 90 seconds; 40 cycles of 93oC for 30 seconds, 57oC for 30 seconds and 
65oC for 3 minutes; 65oC for 10 minutes and hold at 4oC. A 1358 bp product 
corresponds to wild type allele, and a 1107 bp product corresponds to mutant 
rap1a allele. 
 
9. Transfection of siRNA 
siRNAs (Set I) against human rap1a or rap1b gene as previously 
described (96) were synthesized by Ambion (Austin, TX, USA). Non-targeting 
control siRNAs were purchased from Dharmacon (siControl #2 and #3, 
Dharmacon, Lafayette, CO, USA). siRNAs were transfected into HMVECs or 
U373 cells using Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA) per 
manufacturer?s HMVEC or mammalian cell siRNA transfection protocols, 
respectively. Additional Stealth rap1a siRNA pool (Invitrogen) and rap1b 
SMARTpool (Dharmacon) siRNAs were used for confirmation of findings (Set II). 
Sequences within the Set II pools were distinct from those in reference (96).  
 
10. Western blot 
For detecting Rap1 level, cell lysates were resolved by SDS-PAGE 
followed by immunoblot with anti-total-Rap1 and anti-GAPDH (Biodesign, Saco, 
ME, USA) antibodies. For detecting phospho-ERK1/2, phospho-p38, phospho-
Akt and phospho-S6 levels, cells were lysed with phospho-Tyr protecting lysis 
buffer (1% Triton X-100, 10% Glycerol, 50 mM NaCl, 50 mM HEPES, 2 mM 
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EDTA, 1 mM Na3VO4, 10 mM NaF, 10 mM NaPO4, 10 mM p-nitro phenyl 
phosphate, 10 mM ?-glycerol phosphate and protease inhibitor cocktail). 
Samples were subjected to SDS-PAGE and immunoblotted with anti-phospho 
ERK1/2, p38, Akt or S6, and anti-total ERK1/2, p38, Akt or S6 antibodies (Cell 
Signaling). 
 
11. Small GTPase activation assays 
11.1. Rap1 activation assay 
For HMVECs, cells were deprived of serum and growth factors for 18 
hours and stimulated with 25 ng/mL FGF2. For U373, cells were deprived of 
serum for 18 hours and stimulated with 10% FBS. Cells were lysed with Ral lysis 
buffer (50mM Tris pH 7.4, 200 mM NaCl, 2.5 mM MgCl2, 10% glycerol and 1% 
Triton X-100). GTP-Rap1 was pulled down using RalGDS-RBD-GST immobilized 
to glutathione agarose beads (Sigma) and detected using anti-Rap1 antibody 
after SDS-PAGE (115). 
 
11.2. Rac activation assay 
For HMVECs, cells transfected with different siRNAs were deprived of 
serum and growth factors for 18 hours and stimulated with 25 ng/mL FGF2 and 
10 μg/mL Heparin. For U373, cells were serum-deprived for 18 hours before the 
assay. GTP-Rac was pulled down using GST-PAK1-RBD immobilized to 
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glutathione agarose beads (116) and detected using anti-Rac antibody (Upstate 
Biotechnology, Lake Placid, NY, USA) after SDS-PAGE. 
 
11.3. Ras activation assay 
U373 cells were deprived of serum for 18 hours and stimulated with 2% 
FBS for 10 minutes. GTP-Ras was pulled down using GST-Raf1-RBD 
immobilized to glutathione agarose beads and detected using anti-H-Ras or anti-
K-Ras antibodies after SDS-PAGE. 
 
12. Transwell chemotaxis assay 
Transwell filters with 8 μm pore size were coated with 10 μg/mL rat-tail 
collagen I, 5 μg/mL fibronectin, 2 μg/mL vitronectin or 5 μg/mL laminin at 4oC 
overnight, and washed once with PBS. For HMVECs, 2x104 cells in 300 μL EBM-
2 were plated in the Transwell cup. Six hundred μL EBM-2 ± 60 nM FGF2 were 
added to the bottom chamber. Cells were allowed to migrate for 3 hours. For 
U373, 3x104 cells in 300 μL RPMI 1640 were plated in the Transwell cup. 600 μL 
RPMI 1640 plus 2% FBS were added to the bottom chamber. Cells were allowed 
to migrate for 6 hours. To stop migration, medium in the Transwell cup was 
aspirated and the filter was gently swabbed to remove residual cells. Cells that 
had migrated to the reverse side of the filter were fixed in 100% methanol for 15 
minutes before stained in Gram?s crystal violet solution (Sigma) for another 15 
minutes. The filter membrane was washed extensively in water and air-dried 
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overnight. Photographs were taken under a Nikon Diaphot 300 inverted 
microscope at 10x magnification using an attached Nikon Coolpix 995 camera. 
Total number of cells migrated was measured using ImageJ software (NIH). 
 
13. Wound-healing assay 
HMVECs or U373 cells were seeded on 60 mm dishes at 8x105 cells/plate 
(for HMVECs) or 5x105 cells/plate (for U373), and transfected with different 
siRNAs. Cells were cultured for 2 days after transfection to reach confluency. The 
cell monolayer was scraped with a sterile razor blade to remove cells in one 
direction as well as to create a small incision on the plate to mark the start line of 
cell migration. The plate was washed twice with PBS to remove floating cells and 
incubated with either EBM-2 basal medium supplemented with 25 ng/mL FGF2 to 
stimulate HMVEC migration, or RPMI 1640 supplemented with 10% FBS to 
stimulate U373 migration. Photographs were taken after 24 hours and distance of 
cell migration was measured using ImageJ software (NIH). 
 
14. Adhesion assay 
A 96-well plate was coated with 10 μg/mL rat-tail collagen I (BD 
Biosciences), 5 μg/mL fibronectin (Sigma), 2 μg/mL vitrogentin (Sigma) or 5 
μg/mL laminin (Sigma) at 4oC overnight. The wells were washed twice with PBS 
and blocked in 1% BSA at 37oC for 1 hour. For HMVECs, 1x104 cells in 50 μL 
EBM-2 medium were plated in each well. For U373, 1x105 cells in 50 μL 10% 
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FBS, RPMI 1640 were plated in each well. HMVECs were allowed to adhere for 
30 minutes, and U373 cells were allowed to adhere for 1 hour, before washing 
twice with PBS and fixing in 10% methanol, 10% acetic acid. The fixed cells were 
stained for protein with 0.5% crystal violet (Sigma), 10% methanol for 10 minutes. 
The wells were then washed extensively with PBS, the dye dissolved in 10% 
acetic acid, and absorbance at 600 nm wavelength measured using a Spectra 
Max 250 plate reader (Molecular Devices, Sunnyvale, CA, USA). 
 
15. Transwell permeability assay 
Twenty-four mm Transwell (BD Biosciences) filters with 0.4 μm pore size 
were coated with 10 μg/mL rat-tail collagen I at 4oC overnight and washed twice 
with PBS. HMVECs transfected with various siRNAs were plated onto the filters 
at 2x105 cells/well in EGM-2 mv. Cells were cultured for 48 hours to reach 
confluency. Transendothelial resistance (TER) was measured using an Evom 
voltohmmeter (World Precision Instruments, Sarasota, FL, USA). 
 
16. In vitro endothelial tube formation assay 
HMVECs transfected with siRNAs were seeded on growth factor reduced 
Matrigel at 1x104 cells/ well in a 96 well plate in EBM-2 supplemented with 25 
ng/mL FGF2 or PBS. Cells were cultured for 12 hours and photographs taken at 
4, 8 and 12 hours. Photos were processed using Photoshop software (Adobe 
Software, San Jose, CA, USA). 
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17. Proliferation assay 
HMVECs transfected with siRNAs were seeded at 1x104 cells/well in a 96-
well plate and cultured overnight in EGM-2 mv medium. The cells were then 
washed twice with PBS and cultured in 100 μL EBM-2 supplemented with 
different concentrations of FGF2 for 72 hours. U373 cells transfected with 
siRNAs were seeded at 1x104 cells/well in a 96-well plate and cultured in 100 μL 
RPMI 1604 supplemented with different concentrations of FBS for 72 hours. Cell 
proliferation was measured using CellTiter 96 proliferation assay kit (Promega, 
Madison, WI, USA) per manufacturer?s protocol. 
 
18. In vitro invasion assay 
Growth factor reduced Matrigel was thawed and kept on ice. 25 μL of 
Matrigel was added and spread well onto Transwell filter of 8 μm pore size. The 
Matrigel was allowed to polymerize for 30 minutes in the incubator. U373 cells 
transfected with control, rap1a or rap1b siRNAs were suspended in serum-free 
RPMI 1640 and 3x104 cells in 300 μL RPMI 1640 were plated in the Transwell 
cup. Six hundred μL RPMI 1640 plus 10% FBS were added to the bottom 
chamber. Cells were allowed to invade through Matrigel for 20 hours. To stop 
invasion, media in the Transwell cup were aspirated and the filter was gently 
swabbed to remove residual cells. Cells that had migrated to the reverse side of 
the filter were fixed in 100% methanol for 15 minutes before stained in Gram?s 
crystal violet solution (Fluka, Sigma) for another 15 minutes. The filter membrane 
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was washed extensively in water and air-dried overnight. Photographs were 
taken under a Nikon Diaphot 300 inverted microscope at 100x magnitude using 
an attached Nikon Coolpix 995 camera. Total number of cells migrated was 
measured using ImageJ software (NIH). 
 
19. In vitro MMP activity assay 
U373 cells transfected with different siRNAs were washed twice with PBS. 
For each wash, cells were kept in PBS for 10 minutes in the incubator. Cells were 
cultured in serum-free RPMI 1640 in minimum volume for 24 to 36 hours. The 
conditioned media were centrifuged at 1000 rpm for 5 minutes to remove cell 
debris. The cleared media were then concentrated with the Amicon Ultra 
Centrifugal Filter Devices (10k MW cut-off) (Millipore) per manufacturer?s 
protocol. Appropriate amount of sample adjusted to the volume of the retentate 
was mixed with loading buffer without any reducing agents. The samples were 
loaded onto 10% SDS-PAGE gel supplemented with 2 mg/mL gelatin. The gel 
was soaked in 2% Triton X-100 in water for 1 hour to displace SDS and 
incubated overnight at 37oC in renature buffer (50 mM Tris, 150 mM NaCl, 10 
mM CaCl2 at pH 7.4~7.8). The following day, the gel was stained with 0.5% 
Coomassie Brilliant blue and destained briefly until white bands emerge. 
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20. Statistical analysis 
Data from mouse Matrigel and aortic ring assays were analyzed with one-
way ANOVA. Date from all other experiments were compared and analyzed 
using the Student?s t test. A p value < 0.05 was considered significant. 
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RESULTS 
Chapter 1: Rap1a small GTPase plays important roles in mouse 
development 
Previous research in the Quilliam lab has established multiple defects of 
the rap1a knockout mouse in macrophage phagocytosis and neutrophil 
superoxide production. I have also found that mouse embryonic fibroblasts 
(MEFs) and macrophages from rap1a null mice have decreased adhesions on 
plastic surface or various extracellular matrices (Figure 1-1). Further 
characterization of rap1a knockout mice unraveled additional systemic defects. 
The first generation of homozygous knockout mice produced by breeding 
heterozygotes (derived from mating the founder with C57BL/6J) followed near 
perfect Mendelian inheritance (24.9%). However, after backcrossing mice into the 
C57BL/6J strain for an additional five generations, an embryonic lethality of about 
40% in the rap1a knockout mice was observed in heterozygous breeding. 
Dissection of mice embryos at embryonic day 14.5 revealed that some rap1a null 
embryos suffer from edema (Figure 1-2 by Chen and Shou). As embryonic 
edema is usually a result of inefficient circulation, hearts from embryos of 14.5 
and 18.5 days were dissected for examination. Cardiac defects including 
underdeveloped ventricle walls and unsealed interventricular septa were 
observed (Figure 1-3 by Chen and Shou). Besides developmental cardiac 
defects, adult rap1a-/- mice of 9 months or olded exhibited 15% higher heart-to-
total body weight ratio than wild type mice (WT 5.29±0.19 vs. KO 6.09±0.72), 
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suggesting the existence of cardiomegaly (Figure 1-4). Comparison of cardiac 
myocyte sizes revealed that the rap1a null mice suffer from cardiac hypertrophy 
(Ohio State University, unpublished data). These data suggest that Rap1a plays 
a critical role in the circulation system during mouse development and warrant 
further investigation into whether Rap1a and/or Rap1b are required for the proper 
function of other organ systems. 
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Chapter 2: Rap1a and Rap1b are both required for endothelial cell 
functions during angiogenesis 
2.1. Rap1a null mice had defective angiogenesis stimulated by FGF2 
The Quilliam lab, as well as others, has previously shown that the 
activation of Rap1 in endothelial cells by a Rap1 specific agonist 8Cpt-cAMP 
significantly tightens cell-cell junction mediated by VE-cadherin ligation (91-93). 
This action decreased endothelial monolayer permeability, as assessed by 
reduced transendothelial migration of leukocytes (93). The increase in vessel 
permeability allows for the sprouting of endothelial cells, and is a key early step 
during angiogenesis. Therefore, it is suggestive that Rap1 imposes an 
antagonistic effect on angiogenesis. I first sought to determine whether loss of 
the Rap1a protein, one of the two closely related Rap1 family members, would 
impact the angiogenic potential in mice. Vascular endothelial growth factor 
(VEGF) is the most widely used pro-angiogenic factor that induces vessel 
leakage and stimulates angiogenesis potently. It is also frequently secreted by 
tumors under hypoxic conditions to promote tumor angiogenesis. For this reason, 
VEGF was first used to evaluate the angiogenic response of rap1a null mice. The 
wild type and rap1a-/- mice were injected with Matrigel supplemented with PBS or 
appropriate growth factor dosages. However, under two different concentrations, 
VEGF did not strongly stimulate blood perfusion in the assay, and there was no 
significant difference in the hemoglobin content within the gel between the wild 
type and rap1a knockout mice (Figure 2-1). To determine whether there exists a 
37 
growth factor-specific response, I repeated the experiment with fibroblast growth 
factor 2 (FGF2), another pro-angiogenic growth factor. Surprisingly, in contrast to 
the robust angiogenic response to FGF2 in wild type mice that led to a threefold 
increase in the hemoglobin content of Matrigel plugs, FGF2 stimulation resulted 
in little or no blood perfusion in the rap1a-/- mice (Figure 2-2A). Furthermore, 
immunofluorescence staining confirmed the reduced number of CD31-positive 
endothelial cells migrating into the Matrigel plugs implanted in the rap1a-/- mice 
(Figure 2-2B). 
Besides endothelial cells, other cell types, such as pericytes and 
inflammatory cells, could also contribute to the angiogenic process (75). We have 
previously established that Rap1a deficiency caused leukocyte dysfunction (114). 
In order to assert that the dampened angiogenesis observed for rap1a-/- mice 
mainly resulted from defects in endothelial cell functions, I next measured the 
ability of endothelial tube outgrowth from small slices of aorta induced by growth 
factors. Wild type aortic rings had profound endothelial cell-derived tube 
sprouting and branching upon FGF2 stimulation. However, rings dissected from 
Rap1a null mice exhibited only minimal tube outgrowth and branching under the 
same condition (Figure 2-3). These findings strongly suggest that endothelial cell 
defects may directly account for the attenuated angiogenesis observed in rap1a-/- 
mice. Confirming the Matrigel experiment, VEGF treatment yielded 
indiscriminable outcome on aortic tube outgrowth between wild type and rap1a 
knockout mice (data not shown). 
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2.2. Endothelial cells deficient of either Rap1a or Rap1b had altered cellular 
behavior 
The ultimate goal of this study is to gain a better understanding of the 
human system, and to provide a model system to study human diseases in a 
more physiological context. To this end, I began to determine if Rap1 mediated 
similar events in cultured human cells. Given the high similarity of Rap1a and 
Rap1b, the two Rap1 family members, I also wished to investigate whether any 
of the observed endothelial defects were Rap1a or Rap1b specific. Therefore, 
two sets of siRNAs against either rap1a or rap1b were utilized and tested. The 
first set of siRNAs was able to specifically knockdown targeted protein 
exogenously expressed in 293T cells without affecting the other protein. They 
also successfully reduced endogenous protein expression levels in human 
microvascular endothelial cells (HMVECs) (Figure 2-4A). In order to prove that 
any phenotype observed is not due to off-target effect of the siRNAs, a second 
set of pooled siRNAs was used. They were also able to reduce the protein 
expression of the designed genes (Figure 2-4B). 
 
2.2.1. Rap1a or Rap1b depletion impaired endothelial monolayer integrity 
As Rap1 activation has been shown to directly increase VE-cadherin 
activity, I first tested if loss of either Rap1a or Rap1b would impair the ability of 
endothelial cells to form an intact monolayer. HMVECs were plated on Transwell 
membranes following transfection with various siRNAs. Cells were allowed 24 
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hours to re-establish cell-cell contact and form monolayer before transendothelial 
resistance was measured by placing electrodes on both sides of the monolayer. 
Endothelial cells lacking either Rap1a or Rap1b exhibited decreased resistance 
(Figure 2-5), suggesting inefficiency in establishing cell-cell junctions and 
increased permeability. 
 
2.2.2. Rap1a or Rap1b depletion decreased endothelial cell adhesion and 
migration 
Endothelial cell migration is an essential step during angiogenesis. 
Previous research has shown that inactivation of all Rap family members 
including Rap1a, -1b, -2a, -2b, and -2c, by Rap1GAP impaired HUVEC migration 
in a wound-healing assay (43), suggesting that the Rap family play important 
regulatory roles in endothelial cell movement. To further dissect the individual 
impacts Rap1a and Rap1b exert on endothelial cell migration, I first utilized a 
Transwell chemotaxis assay where endothelial cells migrate through a porous 
membrane toward higher FGF2 concentration. This assay best imitates the in 
vivo situation where endothelial cells migrate to the hypoxic region, the source of 
growth factor release. FGF2 is not a strong chemoattractant for endothelial cell 
migration. Under basal conditions, transfection of rap1a, rap1b or both siRNAs 
resulted in a reduced number (~30%) of cells migrated through collagen I coated 
membrane (Figure 2-6A). When FGF2 was applied to the bottom chamber of the 
Transwell plate, a small but significant (approximately 1.5 fold) increase in cell 
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migration was seen with control siRNA treated cells. On the other hand, the 
number of cells migrated toward FGF2 remained the same in cells treated with 
various rap1 siRNAs (Figure 2-6A). To more clearly assess the basic migratory 
function of cells depleted of Rap1, an alternative assay was used. Specific siRNA 
treated HMVEC monolayers were scratch-wounded, and monitored for cell 
migration into the cleared areas. rap1a or rap1b knockdown caused dramatically 
delayed directional migration of cells compared with control cells (Figure 2-6B & 
C). The combination of the chemotaxis and wound-healing assays suggest that 
Rap1 plays important roles in both cell migration and cell response to FGF2. 
Cell migration is largely achieved by the regulation of integrin-mediated 
adhesion at both the leading and the trailing edges of a cell. Since one of the 
important functions of Rap1 is to promote inside-out signaling to trigger integrin 
activation, it is possible that loss of Rap1 also led to reduction in endothelial cell 
adhesion, which may explain the slow migratory rate. Indeed, depletion of either 
Rap1a or Rap1b by siRNA resulted in a decrease of HMVEC adhesion to both 
collagen and fibronectin (Figure 2-7). Furthermore, the combination of both rap1a 
and rap1b siRNAs had an additional 10% decrease in cell adhesion (Figure 2-7). 
 
2.2.3. Decreased cellular proliferation in endothelial cells depleted of 
Rap1a or Rap1b 
Proliferation of endothelial cells is an integral part of angiogenesis, and 
Rap1 has been associated with cellular proliferation in various cell types (117). I 
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therefore sought to determine whether the proliferative rate was affected by Rap1 
deficiency in endothelial cells. HMVECs transfect with rap1 siRNAs were cultured 
with different concentrations of FGF2 to stimulate proliferation. At FGF2 
concentrations of 1, 3, 10, and 25 ng/mL, there were modest yet statistically 
significant decreases in endothelial cell proliferation (Figure 2-8), indicating that 
Rap1 may also participate in the regulation of endothelial cell growth. 
 
2.2.4. Knocking down Rap1a or Rap1b abolished endothelial tubule 
formation 
In order to further validate the use of Rap1a-deficient mice as an animal 
model to study human angiogenesis-related diseases, and to verify the critical 
role of Rap1 in endothelial cells during FGF2-induced angiogenesis, I performed 
an in vitro endothelial tube formation assay that best resembles capillary 
formation in vivo. When plated on Matrigel, cells transfected with control siRNA 
developed an intricate web of tubular structures upon stimulation with FGF2. 
However, suppressing endothelial expression of Rap1a or Rap1b drastically 
reduced the formation of tubes (Figure 2-9), recapitulating the phenotype of 
rap1a-/- mice in the Matrigel plug assay. 
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2.3. Rap1 mediates important cellular signaling events in response to FGF2 
in endothelial cells 
2.3.1. Rap1 was activated by FGF2 in endothelial cells 
The rap1a knockout mice had a blunted angiogenic response to FGF2 but 
not VEGF. HMVECs when depleted of Rap1 also exhibited retarded cellular 
functions. These intriguing results obtained suggested that Rap1 might be a 
required mediator of FGF2-induced signaling events during the angiogenic 
process. Consistent with this notion, FGF2 induced a rapid Rap1 activation in 
HMVECs within 3 minutes that was sustained for at least 60 minutes (Figure 2-
10A & B). To exclude the possibility that Rap1 may also regulate FGF receptor 
expression, total FGF receptor expression level was examined in cells 
transfected with rap1 siRNAs. Knocking down rap1 had no effect on FGFR-1 
expression in HMVECs (Figure 2-10C). 
 
2.3.2. Rac activation by FGF2 was abolished in endothelial cells depleted of 
Rap1 
During endothelial tube formation, cells undergo extensive morphological 
changes. The Rho family GTPase Rac is a major regulator of actin cytoskeleton 
rearrangement, and inhibition of Rac activity abolished endothelial cell tube 
formation on Matrigel (118). Since Rac has been shown to be a downstream 
effector of Rap1 (13), I then sought to determine if Rap1 mediated FGF2-induced 
Rac activation. Transfection of either rap1a or rap1b siRNA completely abolished 
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Rac activation stimulated by FGF2 (Figure 2-11), placing Rap1 upstream of Rac 
in regulating endothelial cell actin cytoskeleton organization. 
 
2.3.3. MAPKs phosphorylation was reduced by Rap1 knockdown 
ERK has been shown to play vital roles in FGF2 signaling to promote 
endothelial cell proliferation and vascularization (119). FGF2 induced ERK 
phosphorylation in HMVECs within 10 minutes and sustained for at least 60 
minutes (Figure 2-12A). Since Rap1 can activate ERK in cell types that express 
B-Raf, I next tested if defective endothelial cell functions could be attributed to 
reduced ERK activation. Depletion of either Rap1a or Rap1b resulted in about 
50% reduction in ERK1/2 phosphorylation in response to FGF (Figure 2-12B & 
C), suggesting that Rap1 couples FGF signaling to ERK phosphorylation in 
endothelial cells during angiogenesis. 
Since VEGF stimulation in the rap1a null mice elicited an equally robust 
angiogenic response as in the wild type mice, I then tested if Rap1 mediates 
VEGF-induced ERK phosphorylation in endothelial cells. ERK1/2 was potently 
activated by VEGF-A after 10 minutes stimulation, and this activation was not 
reduced by the treatment of either rap1 siRNA (Figure 2-13). 
In addition to ERK, another MAPK, p38 has also been shown to be 
important for endothelial cell migration and angiogenesis (119). The 
phosphorylation of p38 induced by FGF2 was rapid but transient, peaking at 10 
minutes (Figure 2-14A). Similar to ERK, this activation was also significantly 
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reduced when HMVECs were transfected with either rap1 siRNA (Figure 2-14B & 
C). 
Besides the two MAPKs, I have also tested if Rap1 regulates focal 
adhesion kinase Pyk2 during cell migration and adhesion. Pyk2 phosphorylation 
has been reported to be downstream of Rap1 activation in some cell types (90, 
120), however, in HMVECs, FGF2 stimulation did not induce Pyk2 
phosphorylation (Figure 2-15). 
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Chapter 3: Rap1 regulates glioblastoma malignancy 
Overexpression of Rap1 or increased Rap1 activity due to loss of 
Rap1GAP has been shown to occur in multiple glioblastoma samples (111-113). 
These findings, together with Rap1?s important roles in regulating cell migration, 
proliferation and differentiation, imply that this GTPase may be a key player in 
glioblastoma malignancy. In this chapter, I wished to explore whether Rap1 
inhibition could reduce glioblastoma cell malignancy. 
 
3.1. Loss of Rap1b induced morphological changes in glioblastoma cells 
To determine whether Rap1a or Rap1b contributes to the malignancy of 
GBM, a highly invasive glioblastoma cell line U373-MG was used and treated 
with specific rap1 siRNAs. Normal U373 cells cultured in the presence of serum 
exhibited a highly migratory phenotype with a large fan-shaped leading edge and 
very few cellular processes (121) (Figure 3-1A). Interestingly, knocking down 
rap1b induced a notable morphology change in U373 cells. These cells have a 
small rounded cell body, with 2 to 3 long extruding cytoplasmic processes (Figure 
3-1A). The transfection of rap1a siRNA, on the other hand, only induced a 
marginal change in cell morphology, with a slight elongation of cell shape (Figure 
3-1A). Accompanying morphological changes, the activation level of Rac, a 
regulator of cytoskeleton rearrangement, was greatly increased in rap1b siRNA 
transfected cells compared to control or rap1a siRNA treated cells (Figure 3-1B). 
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To confirm that this finding was not due to side effects of siRNA 
transfection, U373 cells were also infected with lentiviruses that produce 
scramble, rap1a or rap1b shRNAs. A total of 4 rap1a and 4 rap1b shRNAs were 
tested for their effects on cell morphology and rap1 silencing. rap1a shRNA #1 
caused a 90% reduction in total Rap1 level, and a near complete loss in Rap1-
GTP in cells. As a result, massive cell death was observed. rap1a shRNA #2 
caused partial reduction in Rap1b protein expression. rap1a shRNA #4 induced a 
spiky morphology in U373 cells, with multiple short cellular protrudings. Although 
total Rap1 protein level was reduced by the infection of this shRNA, the Rap1-
GTP level remained the same, suggesting compensatory elevation in Rap1b 
protein level. Both rap1a shRNAs #3 and #5 increased Rap1b protein level. 
rap1b shRNA #2 completely knocked down rap1b expression in U373 cells, and 
reduced total Rap1 protein level by 70%. However, total Rap1-GTP level was not 
changed, indicating hyperactivation of Rap1a proteins. This is correlated with a 
well spread and flat cell phenotype, similar to the effect of the transfection of 
Rap1a into NIH 3T3 cells (122) (Figure 3-2). 
 
3.2. Reduced invasiveness of glioblastoma cell depleted of Rap1b 
High Rap1b expression levels have been associated with highly invasive 
glioblastomas (111). The observed changes in cell shape resemble a more 
terminally differentiated cell type, and suggest that glioblastoma malignancy may 
directly correlate with Rap1b activity. I then sought to examine whether depletion 
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of Rap1b in U373 cells would decrease their invasiveness. U373 cells transfected 
with rap1b siRNA had dramatically reduced invasion through Matrigel in 
response to serum attraction (Figure 3-3). Cells depleted of rap1a, however, did 
not exhibit such a reduction in their invasiveness. 
 
3.3. MMP production was decreased with loss of Rap1 
During cancer invasion into nearby tissues, tumor cells secrete matrix 
metalloproteinases (MMPs) to digest basement membrane proteins followed by 
integrin-dependent migration. There is evidence that Rap1 may regulate MMP 
production in some cells, although a common agreement has not yet been 
reached (95, 123, 124). I thus decided to examine the activities of secreted 
MMPs in U373 cells transfected by various rap1 siRNAs. In the MMP 
zymography assay, MMP2 activity in conditioned medium from cells treated with 
rap1b siRNA dropped to only 20% of that from control cells (Figure 3-4). 
Depletion of Rap1a in U373 cells also caused a decrease in MMP2 activity, 
however, to a much lesser extent than the knockdown of rap1b (Figure 3-4). 
Integrins have been associated with MMP activities (125-127). Since one 
of the established functions of Rap1 is to regulate “inside-out” integrin signaling, it 
is possible that the activities of certain integrins were down-regulated by rap1b 
silencing, contributing to reduced MMP2 activity. To verify this, U373 cells 
transfected with control, rap1a or rap1b siRNAs were plated on different 
extracellular matrices. Cells did not adhere to laminin very tightly, and there was 
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no difference in adhesion to vitronectin (Figure 3-5). However, a 20% decrease in 
adhesion to collagen I and fibronectin was observed in rap1b, but not in rap1a 
siRNA treated cells (Figure 3-5). 
 
3.4. U373 migration was not affected by the loss of either Rap1 
Modulation of integrin activities is a vital part of cell movement, and Rap1 
plays important roles during cell migration in many cell types. I next wanted to 
explore whether the reduced invasiveness of U373 was also caused by a 
decrease in integrin-dependent migration. To achieve this goal, the Transwell 
chemotaxis assay was used. In choosing the chemoattractant for this assay, I 
tested PDGF, EGF, FGF and fetal bovine serum (FBS), all of which have been 
shown to act on glioblastomas (128). However, only EGF and serum stimulated 
Rap1 activation in U373 cells following various length of stimulation. Ten percent 
FBS potently activated Rap1 at 1 minute and this activation prolonged for at least 
30 minutes (Figure 3-6A). Rap1 activation by 15 ng/mL EGF peaked at 10 and 30 
minutes, and diminished at 60 minutes (Figure 3-6B). 
The use of EGF did not induce U373 cell migration on collagen I coated 
Transwell membrane (Figure 3-7A). Two and 10% FBS, on the other hand, 
attracted U373 cells to migrate through collagen-coated filter. However, no 
significant difference in the number of cells migrated was observed between 
control, rap1a or rap1b siRNA treated groups. Since others have noted that there 
exist specific-integrin dependent cell responses, multiple extracellular matrix 
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proteins that activate different integrin combinations were used in the chemotaxis 
assay, namely collagen, fibronectin, vitronectin, and laminin. Although the 
potential of U373 cells to migrate on each matrix is different, no significant 
difference was observed between the control, rap1a or rap1b siRNA (Figure 3-
7B). 
Next, the scratch wound-healing assay was utilized to measure the basic 
migratory ability of U373 cells stimulated by 10% serum. In this assay, however, I 
observed a 15% decrease in the area migrated over 24 hours in the siRap1a 
group, and a 20% decrease in the siRap1b group, when compared to the control 
group respectively (Figure 3-8). 
 
3.5. Rap1 antagonizes Akt, S6 and p38 phosphorylation through inhibition 
of ERK 
Suppression of Rap1 expression in endothelial cells and many other cell 
types could cause a decrease in the activation of important signaling molecules, 
such as ERK1/2, p38 and Akt. The unique phenotype that only rap1b knockdown 
led to reduced malignancy of U373 cells also prompted me to investigate whether 
there is Rap1b depletion-specific down-regulation in any intracellular signaling 
pathway. To this end, U373 cells transfected with control, rap1a or rap1b siRNAs 
were stimulated with 10% FBS for 10 minutes, and the phosphorylation of 
ERK1/2, Akt, p38 and S6 was measured. The phosphorylation levels of these 
proteins, however, were indistinguishable between different siRNA treated 
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groups (Figure 3-9A). Since 10% FBS induced a highly robust activation of these 
signaling molecules, it is possible that the effect of Rap1 depletion would be 
masked. Therefore, 2% FBS was used to stimulate cells. Surprisingly, knocking 
down rap1 did not decrease protein phosphorylation, but instead potentiated the 
activation of ERK1/2, p38, Akt and ribosomal S6 protein (Figure 3-9B & C). In 
addition, unlike what was observed in the invasion and MMP activity assays, 
depleting Rap1a or Rap1b had similar effects in elevating ERK1/2, p38, Akt and 
S6 phosphorylation states. 
It has been reported that astrocytes do not express B-Raf (129). As Rap1 
exerts an antagonistic role on the c-Raf-1/MEK/ERK pathway, it is a plausible 
elaboration that in astrocyte-derived glioblastoma multiform U373 cells, Rap1 
depletion would release sequestered c-Raf-1, and elevated ERK1/2 
phosphorylation level. There have been implications that ERK1/2 may cross-talk 
to other MAPK family members, and other signaling molecules, such as S6 (130, 
131), p38 (132) and Akt (133). In order to investigate whether the up-regulation of 
Akt, p38 and S6 was due to the activation of ERK1/2, a MEK1/2 specific inhibitor, 
U0126, which prevents ERK1/2 phosphorylation, was used. U373 cells 
transfected with various siRNAs were subjected to 10 μM U0126 pre-treatment 
for 30 minutes before stimulated with 2% FBS for 10 minutes. The MEK1/2 
inhibitor completely blocked ERK1/2 phosphorylation without affecting its 
expression level (Figure 3-10). Under the basal condition, the Akt 
phosphorylation levels were higher in rap1a or rap1b siRNA treated cells (Figure 
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3-10). After U0126 pre-treatment, however, p-Akt levels in rap1 siRNAs 
transfected cells were reduced to the same as in control siRNA transfected cells, 
and 2% FBS stimulation failed to induce Akt phosphorylation in any groups 
(Figure 3-10), suggesting an indispensable role of ERK1/2 during Akt activation 
in U373 cells. In the presence of MEK inhibitor, 2% FBS was able to activate 
p38. ERK1/2 inhibition eliminated the difference in p38 phosphorylation levels 
between control and rap1 siRNAs treated cells (Figure 3-10). The 
phosphorylation of S6 was up-regulated by serum stimulation, however, rap1a or 
rap1b knockdown reduced S6 activation when ERK1/2 was inhibited (Figure 3-
10). This suggests that besides its negative effect on S6 phosphorylation through 
ERK inhibition, Rap1 could also activate S6 in an ERK-independent pathway. 
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DISCUSSION 
Chapter 1: Rap1a small GTPase plays important roles in mouse 
development 
Previous characterization of the rap1a knockout mouse in our lab has 
been focused on myeloid cell dysfunctions, such as macrophage phagocytosis, 
leukocyte migration and neutrophil superoxide production. However, given its 
ubiquitous expression and regulation of cell adhesion and cell junction formation, 
it was expected that more systemic defects of the rap1a knockout mouse would 
emerge. Indeed, the rap1a-/- and rap1b-/- mice suffered from ~40% and ~85% 
embryonic lethality, respectively. The attempt to generate viable rap1a and rap1b 
double knockout mouse was unsuccessful. This is consistent with the report that 
the deletion of the single rap1 gene in Drosophila was lethal at the larval stage 
(134). This suggest that some functional redundancy may exist between Rap1a 
and Rap1b, and that the partial lethality observed in rap1a or 1b knockout mouse 
may be a result of insufficient compensation from each other. Recently, the 
noncanonical Wnt signaling has been found to regulate zebrafish and Xenopus 
gastrulation. Wnt-8 could activate Casein kinase I epsilon (CKI?) to 
phosphorylate and inactivate SIPA1L1, a Rap GAP, thereby increasing Rap1 
activity. Inhibition of Rap1 activation resulted in failure of gastrulation and 
shortened anterior-posterior axis (135). It therefore implies that Rap1 activity is 
required for morphogenesis during gastrulation. Those mouse embryos that 
failed to upregulate rap1b expression to compensate for the loss of rap1a could 
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die of insufficient Rap1 activity. An evidence is that in 2 out of 3 rap1a null 
neutrophil samples examined, Rap1b expression was noticeably elevated (Figure 
D1). However, the detailed mechanism is still enigmatic. 
We have also found developmental cardiac defects at E14.5 and E18.5 in 
a number of rap1a null embryos. However, it is unlikely that these defects 
underlie the partial penetrance of rap1a-/- death, as the lethality seemed to occur 
earlier than E9.5. Instead, it is highly possible that most embryos bearing cardiac 
defects eventually developed into viable pups. Supportive of this notion, most 
male rap1a-/- mice examined had cardiac hypertrophy at one year of age or older 
when compared to wild type mice, a likely result of chronic cardiac overload to 
overcome the negative effect of underdeveloped hearts. A similar phenotype was 
observed in the focal adhesion kinase (FAK) conditional knockout mice. When 
FAK was inactivated in embryonic cardiomyocytes, the majority of mice died 
before E16.5 manifesting thin ventricular walls and ventricular septal defects. The 
small fraction of surviving mutant mice all spontaneously developed eccentric 
right ventricle hypertrophy at age of 10-month. Dissection of molecular signaling 
events revealed that phosphorylation of FAK at Y397 is important for its Src-
dependent regulation of myocyte enhancer factor 2a (MEF2a), a transcription 
factor important for myogenesis and cardiac development (136). Rap1 has been 
shown to participate in FAK signaling (137-139) and to be required for FAK 
phosphorylation at Y397 in endothelial cells (140). Therefore, the genetic deletion 
of rap1a possibly reduced the phosphorylation and activation of FAK during 
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mouse cardiac development, resulting in the various defects observed in 
embryonic and adult mice. Furthermore, the Rap1 GEFs, Epac1 and 2, are 
required for cardiac development (141) as well as Ca2+ release and ?-AR 
response in cardiac myocytes (142). The loss of rap1a might dampen the 
myocyte response to trophic signals and lead to heart malformation. Since Rap1 
also plays important regulatory roles in endothelial cell function, and that the 
endocardial layer regulates the myocardium, we shall not rule out the possibility 
that the endocardial cushion also contributes to the cardiac defects of rap1a 
knockout mice. The precise explanation, however, will require extensive research 
proof. 
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Chapter 2: Rap1a and Rap1b are both required for endothelial cell 
functions during angiogenesis 
Multiple lines of evidence have pointed to the involvement of Rap1 in 
endothelial cell function, including migration and junction formation (43, 91-93), 
suggesting that this GTPase may participate in the regulation of angiogenesis, a 
process of capillary formation by endothelial cells. However, a direct link between 
Rap1 and angiogenesis is still lacking. In addition, most previous studies used 
methods that would turn on/off Rap1a, Rap1b, Rap2a, 2b, and 2c in endothelial 
cells at the same time, and thus failed to address whether these two closely 
related Rap family member might play differential roles. My research, for the first 
time, has identified Rap1a as an indispensable factor for FGF2-induced 
angiogenesis in mice, and has also revealed that both Rap1a and Rap1b are 
required for normal endothelial cell function. Loss of expression of either rap1 
gene severely impaired endothelial cell adhesion, migration and cell junction 
formation, and reduced Rac, ERK and p38 activation by FGF2, suggesting that 
Rap1 couples the FGF receptor to multiple downstream pathways to regulate 
endothelial cells during blood vessel formation. 
 
2.1. The requirement of Rap1a during angiogenesis and developmental 
vasculogenesis 
The data I obtained indicated that the loss of Rap1a in mice greatly 
interfered with their angiogenic response to FGF2. This poses the question of 
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whether Rap1a is also required for vascular morphogenesis during embryonic 
development. The connection between Rap1 activity and embryonic 
vasculogenesis is suggested by two independent studies on the two Rap1 GEFs, 
C3G and PDZ-GEF I (RA-GEF I). Mice with a c3g hypomorphic allele died at 
E11.5 due to vascular defects, exhibiting massive hemorrhage and lack of 
pericytes to support vascular integrity (52). PDZ-GEF I is another GEF for Rap1, 
and its expression in mice starts at E8.5. The genetic deletion of this gene in 
mice led to embryonic death by E9.5 that resulted from severe defects in blood 
vessel formation in the yolk sac (143). However, since C3G and PDZ-GEF I 
activate both Rap1a and Rap1b, these reports do not differentiate whether it is 
the inactivation of Rap1a, Rap1b or both that underlies the vascular defects. After 
the completion of this project, Chrzanowska-Wodnicka et al. reported that the 
rap1b-/- mice also exhibited defective angiogenesis (144). The similar phenotypes 
of rap1a and rap1b knockout mice suggest that these two small GTPases are 
both needed for developmental vasculogenesis. Rap1b could compensate for the 
loss of Rap1 during vascular morphogenesis, however, only to a certain extent. 
Supportive of this postulation, we observed tortuous blood vessels in the cornea 
of rap1a null mice (M.E. Hartnett, University of North Carolina and L.A. Quilliam, 
Indiana University, unpublished data), despite the grossly normal look of rap1a-/- 
mice after birth. It is also consistent with the fact that these mice develop cardiac 
hypertrophy as they age, a likely result of developmental cardiac defects. 
Therefore, it is possible that the rap1a-/- mice have a functional yet 
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underdeveloped cardiovascular system, that could be more susceptible to certain 
vascular diseases, and in particular situations, might fail to respond to pro-
angiogenic growth factor challenge. 
 
2.2. Rap1 regulates endothelial cell functions during angiogenesis 
The striking phenotype that the rap1a-/- mice produced very few blood 
vessels in the Matrigel plug assay implicates a severely impaired angiogenic 
response. However, dysfunction of multiple cell types could all result in the 
absence of blood vessel development within the Matrigel plugs implanted in the 
rap1a null mice. Further experimentation with dissected mouse aortic pieces 
demonstrated that Rap1 deficient endothelial cells failed to form tubes and 
branching, suggesting that the impaired endothelial cell functions mainly underlay 
the blunted angiogenesis observed. However, we cannot exclude the possibilities 
that defective pericytes, bone marrow-derived accessory cells and endothelial 
progenitor cells could all contribute to the lack of angiogenesis. Pericytes are 
vascular smooth muscle (vSMC) lineage cells that surround microvessels and 
play important roles in vascular stability. Without the support of pericytes, 
neovessels degenerate rapidly after tubule formation (145). rap1a and rap1b 
mRNA levels as well as Rap1 protein level were up-regulated upon PDGF BB 
stimulation of vSMCs (146, 147). Recently, Rap1 has also been shown to 
participate in vSMC glucose transport (148). It is therefore possible that Rap1 is 
also involved in the regulation of pericyte functions. 
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Macrophages, especially tumor-associated macrophages (TAMs), make 
significant contribution to angiogenesis by releasing a variety of pro-angiogenic 
factors (149). We previously demonstrated that mouse macrophages lacking 
Rap1a have decreased adhesion and chemotaxis. This might hamper the on site 
recruitment of macrophages to promote angiogenesis. Endothelial progenitor 
cells (EPCs) may also aid in neovascularization (150). A recent report showed 
that overexpression of a Rap1 GAP, Spa1, in human CD34+ progenitor cells 
decreased CXCR4 expression by cAMP (151). All these findings suggest that, in 
addition to defective endothelial cells, dysfunction of pericytes, macrophages and 
EPCs could all contribute to the attenuated angiogenesis in our rap1a null mice. 
Angiogenesis is an intricate, multi-step process that requires the 
collaboration of several cellular functions, including loosening and re-establishing 
cell-cell contact, varying cell adhesiveness to achieve migration and rearranging 
cytoskeleton. Increased vascular permeability is usually considered the first step 
in angiogenesis. This lab and others have previously shown that Rap1 is involved 
in the regulation of endothelial cell junction formation. Activation of Rap1 by the 
Epac agonist 8Cpt decreased transendothelial permeability and the expression of 
Rap1GAP disrupted endothelial cell junction (91-93). Therefore it was initially 
anticipated that loss of Rap1a in mice would enhance angiogenesis. However, in 
sharp contrast to the robust angiogenic response observed in wild type mice, 
vessel formation was almost completely absent from the knockouts. This 
suggests that the vessel leakiness due to the loss of Rap1a was not the major 
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determinant of the angiogenic response to FGF2 in mice. It is true that 
endothelial cells depleted of either Rap1a or Rap1b had lower transendothelial 
resistance (TER) after plating on Transwell filters, indicating loose endothelial cell 
junctions. This assay is a reflection of the ability of endothelial cells to re-
establish a monolayer after dissociation from each other, reminiscent of the final 
step in angiogenesis, where endothelial cells make contact with each other as 
well as with pre-existing capillaries. The impaired endothelial cell junctions could 
be largely due to defective VE-cadherin-dependent cell adhesion, a process 
involving Rap1 activity (152), as demonstrated by the disruption of VE-cadherin 
localization at AJ with RapGAP treatment (93). It has been shown that VE-
cadherin is also pivotal in neovessel maturation and stabilization (153). The 
inefficient homophilic ligation of VE-cadherin as a result of the loss of Rap1 may 
thus exert a greater impact on capillary maturation than permitting endothelial 
monolayer leakage. 
One of the key steps during angiogenesis is the migration of endothelial 
cells toward the source of cytokine release. Rap1 has been shown to regulate 
integrin mediated adhesion and cell migration. Loss of C3G, a GEF for Rap1 but 
not Rap2, in mouse fibroblasts resulted in decreased adhesion and enhanced 
haptotaxis (51). Consistent with this, rap1a null macrophages had reduced 
adhesion and chemotaxis (114) and rap1a null MEFs were less adhesive to 
collagen I and fibronectin (Figure 1-1A). The role of Rap1 in endothelial cell 
migration has also been proposed. Rap1 was activated at the membrane ruffles 
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and at the leading edge of migrating endothelial cells (43, 154). Infection of 
HUVECs with adenoviruses encoding rap1GAPII, which inactivates Rap1, greatly 
reduced wound closure in a wound-healing assay (43). Treatment of HMVECs 
with anthrax edema toxin, which elevates intracellular cAMP level and in turn 
activates Epac1/2 leading to Rap1 hyper-activation, impeded with endothelial cell 
chemotaxis to VEGF (155). These findings support the assertion that the proper 
regulation of Rap1 activity is crucial to normal endothelial migration. However, in 
these studies, the employment of Rap GAPs and GEFs may affect Rap1a, 
Rap1b, Rap2a, Rap2b and Rap2c at the same time, making it impossible to 
dissect the specific role of each protein. My research work showed that Rap1a 
and Rap1b were equally important in regulating endothelial cell functions. Given 
the fact that depleting either Rap1 GTPase had similar effects on endothelial cell 
behavior and signal transduction, and that knocking down both of them had little 
additive effect, it is suggestive that these two closely related proteins might 
engage in the same pathway, serving non-redundant functions. The possible 
mechanisms of action include: 1) Rap1a and Rap1b form functional dimers, 2) 
they act in an upstream/downstream manner or utilize different effectors. There 
has been evidence that the Ras family of small GTPases could dimerize in vitro 
and in vivo. Formation of Ras dimers at the plasma membrane was essential for 
Raf-1 activation (156). Rac1 was also shown to oligomerize via its 6 polybasic 
residues at the C-terminal (157). The Rap1a protein also harbors 6 Lysine 
residues separated by a single Proline at the C-terminal (KKKPKKKSCLLL). 
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Rap1b, however, only has 4 basic residues at its C-terminal (GKARKKSSCQLL). 
The attempt to co-precipitate Rap1b with GST-fusion Rap1a and vice versa did 
not reveal any dimerization of the two proteins in 293T cells. However, a more 
optimal condition for this assay may need to be worked out. The formation of Ras 
dimers appeared to be mediated by aggregation of Ras at lipid moieties such as 
liposomes, as elution of bacterially expressed Ras from a gel filtration 
chromatography column only gave monomers, and the attempt to 
immunoprecipitate Ras dimers failed (156). Rac1 dimers were shifted to 
monomers upon increasing the concentration of NaCl from 50 to 300 mM, or of 
MgCl2 from 0.2 to 30 mM (157). In my previous attempts to co-immunoprecipitate 
Rap1a and Rap1b, either RIPA buffer with 150 mM NaCl and strong detergents 
(0.1% SDS and 1% Triton X-100), or Ral lysis buffer with 200 mM NaCl and 2.5 
mM MgCl2 was used to lyse the cells. It is possible that such conditions disrupted 
hydrophobic or ionic interactions, leading to the monomeric exhibition of Rap1 
proteins. In spite of the divergence in their C-termini and a different codon 48 
next to the effector-binding loop, the Rap1a and Rap1b proteins have not been 
shown to bind differentially to effector proteins. Therefore, it is likely that Rap1a 
and Rap1b utilize common downstream effectors. Recently, an independent 
study also demonstrated that silencing of either rap1a or rap1b in HUVECs 
blocked their sprouting under FGF2 stimulation, and reduced endothelial cell 
adhesion and migration (140). Their findings are supportive of my observation 
that Rap1a and Rap1b are both required for functional human endothelial cells. 
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Normal endothelial cells when plated on Matrigel form delicate tubule 
structures when supplied with pro-angiogenic factors. This process requires 
extensive cytoskeletal rearrangements that are mediated by the Rho family 
GTPase Rac. Indeed, this GTPase has been demonstrated to be required for 
endothelial cell tube formation on Matrigel (118, 158). Rap1 can localize the Rac 
GEFs Vav2 and Tiam1 to activate Rac specifically at the leading edge of 
migration and regulate cell morphology (13). It is therefore not surprising that 
silencing rap1 abolished Rac activation and impaired HMVEC tube formation. 
 
2.3. Rap1 is a novel mediator of FGF signaling in endothelial cells 
My observations also established a novel FGF2-Rap1-ERK signaling 
pathway in endothelial cells. ERK1 and ERK2 activities are required for focal 
adhesion and cell migration, and they also modulate Rho family GTPases and 
ROCK function on cytoskeleton (159). It has been found that ERK1/2 play critical 
roles during both developmental neovascularization and pathological 
angiogenesis (119). ERK1/2 phosphorylation by FGF2 was reduced by 50% in 
HMVECs transfected with rap1 siRNAs. One possibility is that Rap1 regulates the 
surface expression of FGF receptors, and depleting Rap1 reduced the number of 
FGF receptor, limiting the amplitude of ERK activation. However, western blotting 
of FGFR-1, the major FGF2 receptor in endothelial cells, showed equal 
expression in each group, suggesting that Rap1 participates in the signal 
transduction from FGF2 to ERK1/2. Ras has been shown to mediate FGF2?s 
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ability to activate ERK and to induce endothelial cell proliferation and 
differentiation (83, 160, 161). For the first time, I have identified that Rap1 also 
transduces FGF2 signaling to activate ERK in endothelial cells. Rap1 activation 
by FGF2 was rapid (detectable at 3 minutes) and sustained (for at least 60 
minutes). Knocking down rap1a or rap1b significantly reduced ERK activation by 
FGF2. Supporting our findings, a previous report showed that the expression of 
dominant negative H-Ras in endothelial cells abrogated Ras activation by FGF2, 
but only partially reduced ERK phosphorylation and failed to block FGF2 induced 
differentiation (162). It is likely that the residual phosphorylation of ERK in the 
absence of Ras activation was mediated by Rap1. Therefore, it is not surprising 
that Ras and Rap1 activate different pools of ERK in cells and the 
phosphorylation of ERK during morphological change or differentiation is 
attributable to Rap1. Since ERK activation could induce cell proliferation, it is 
possible that the reduced phospho-ERK levels resulting from rap1 suppression 
account for the slower proliferative rate of HMVEC. 
Another MAPK, p38, also works downstream of FGF2 to regulate 
endothelial cells during angiogenesis. It has been reported that p38 could exert 
an anti-proliferative and pro-migratory role on endothelial cells. Therefore, p38 
could act in a coordinated fashion with ERK to have a defined modulation of 
endothelial cells during capillary formation. Rap1 has been described both 
upstream and downstream of p38 in other cell types (37, 163). In HMVECs, 
however, FGF2 induced a rapid but transient activation of p38 that was 
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drastically reduced upon Rap1 depletion. This finding places Rap1 upstream of 
p38 regulation in endothelial cells, and suggests that this small GTPase regulates 
the two different MAPKs temporally to promote endothelial tubulogenesis. 
Upon FGF2 binding, FGFR-1, the major FGF receptor in endothelial cells, 
undergoes auto-phosphorylation. The phosphorylated Tyrosine residues provide 
binding sites for multiple signaling molecules, such as Crk and phospholipase C-? 
(PLC-?). Adaptor protein Crk binds to p-Y463 in the juxtamembrane region of 
FGFR-1 (164), and it has the ability to recruit RapGEF1/C3G. Indeed, Crk1, 
Rap1-GTP and Rap1 effector RAPL, all localize at the membrane ruffle or the 
leading edge of HAECs (43, 154). It is thus possible that FGF2 activates Rap1 
via the Crk-C3G axis. PLC-? also binds to FGFR-1 at p-Y766 (82). Upon FGF2 
stimulation, FGFR-1 phosphorylates and activates PLC-? (160) and generates 
second messengers IP3 and DAG. DAG is a physiological activator of PKC, 
however, PLC-? mediated ERK phosphorylation and tube formation in endothelial 
cells by FGF2 was independent of PKC (83, 160). This suggested a different 
signaling pathway downstream of PLC-? regulating these events. RasGRP3, a 
GEF for Rap1 that is activated by DAG and/or Ca2+, has been identified in 
angiogenic vessels (165). It is likely that FGF2 utilizes Crk/C3G and/or PLC-
?/RasGRP3 pathways to spatially and temporally activate Rap1 in endothelial 
cells. 
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Chapter 3: Rap1 regulates glioblastoma malignancy 
In this chapter, I have explored the correlation between Rap1 activity and 
glioblastoma biology. Although previous studies by others have implied that Rap1 
might be involved in glioblastoma malignancy, research on how Rap1 affects 
glioblastoma cell function is still lacking. Through my work, several mechanisms, 
albeit still imperfect, have been proposed. Depletion of Rap1b, by down-
regulating secreted MMP2 activity, reduced glioblastoma cell U373 invasion in 
vitro. Intracellularly, Rap1 inhibits Akt, p38 and S6 phosphorylation by 
antagonizing ERK1/2. 
 
3.1. Rap1 activity and glioblastoma malignancy 
Tumor invasion and metastasis are the major causes of cancer death. In 
the case of brain tumor, advanced glioblastoma invasion into nearby brain tissue 
often undermines the efficacy of surgical, chemo and radiation therapies. The 
observation that loss of Rap1b in U373 cells reduced their invasive behavior 
holds promise for identifying another therapeutic target for GBM treatment, 
however, without a careful dissection of the signaling behind it, this finding will 
have little impact on clinical research. 
The invasion of U373 cells through the thin Matrigel layer toward serum 
was drastically reduced when the cells were treated with rap1b siRNA. This could 
result from a decrease in matrix protein digestion by secreted MMPs, a defect in 
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integrin-dependent migration, a lack of response to serum stimulation, or a 
combination of these conditions. 
Research by others has linked Rap1 to MMPs, however, a definitive 
conclusion has yet to be drawn. Early studies suggested that Rap1 may have a 
negative effect on MMPs. In endothelial cells, treatment with tissue inhibitors of 
metalloproteinase 2 (TIMP-2) increased the expression of RECK, a membrane-
bound MMP inhibitor, via Crk/C3G/Rap1 signaling (95, 166). In squamous cell 
carcinoma, exogenous expression of Rap1GAP, which inactivates Rap1, 
promoted cell invasion and increased MMP2/9 transcription and activities (123). 
On the other hand, a recent study suggests otherwise: The invasion of a prostate 
cancer cell line, PC3, expressing dominant active Rap1 was more sensitive to an 
MMP inhibitor than the vector control cells (124). This report is consistent with my 
finding that the conditioned medium collected from rap1b knockdown cells 
contained less active MMP2 than media from the control or rap1a siRNA groups. 
These confounding observations clearly indicate that tumor behaviors are a 
function of their origin and environment, and warrant further research into 
different types of cancers. 
The reduction in active MMP2 could be a result of decreased MMP2 
expression, impaired secretion, or reduced activation of pro-enzymes. Western 
blotting from the cells producing the conditioned media revealed equal 
expression of MMP2 from the three different siRNAs treated cells, therefore 
suggesting that MMP2 expression in U373 cells is not under the modulation of 
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Rap1. However, caution should be taken in drawing this conclusion, as cells were 
deprived of serum for 24 to 36 hours before conditioned media were collected 
and cells were lysed. Whether cell behaviors with serum stimulation deviate from 
the basal condition will need further investigation. 
A wealth of research has been conducted on how Rap1 regulates 
secretion of insulin, pancreatic digestive enzymes, hormones and 
neurotransmitters (167-169). Rap1 was found attached to the membranes of 
amylase zymogen granules in parotid acinar cells (170) and pancreatic acinar 
cells, and inactivation of Rap greatly reduced enzyme release (171). Epac2, a 
cAMP responsive GEF for Rap1, mediates insulin secretion in pancreatic ? cells 
(167, 172). These previous reports strongly suggest a role for Rap1 in cAMP 
stimulated secretion in various cells. The major trophic constituent in serum is 
lysophosphatidic acid (LPA), which binds to cell surface G protein-coupled 
receptors (GPCRs), and increases intracellular cAMP levels (173). It is therefore 
not surprising that Rap1 depletion may disrupt the secretion of MMP2 in 
glioblastoma cells. 
MMPs are secreted as pro-enzymes that upon release have to be 
converted to their active forms. However, this does not ensure a high activity in 
digesting matrix proteins. The MMPs have to be aggregated to reach a 
concentration high enough for efficient matrix breakdown. Integrins have long 
been identified as binding partners for MMPs that also enhance MMP activity 
(125-127). Rap1 plays a central role in regulating integrin activity in a variety of 
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cells. Indeed, the adhesion of U373 cells to collagen or fibronectin was reduced 
by 20% upon treatment with rap1b siRNA. However, no change was observed in 
cell adhesion to vitronectin. Collagen is the ligand for ?1 family of integrins, 
fibronectin is the ligand for some ?V family of integrins, and vitronectin mainly 
binds to ?V?3. The integrin ?V?3 has been shown to be the major integrin binding 
to MMP2 (126). Data from U373 adhesion assays suggest that the activation of 
?V?3 integrin was not affected by rap1 knockdown. Besides ?V?3, other integrins 
have also been demonstrated as MMP2 activity enhancers. In ovarian carcinoma 
cells, activation of ?3?1 strongly promoted MMP2 activation (174), and blocking 
integrins ?2 and ?1 diminished MMP2 activity (175). Furthermore, integrin 
clustering on collagen I also upregulated the surface expression of membrane 
type 1(MT1)-MMP, an enzyme that cleaves pro-MMP2 to its active form (174). 
Taken together, decreased integrin activation due to loss of rap1b might 
decrease both MMP2 spatial localization and enzymatic activation, resulting in 
reduced matrix digestion during U373 invasion. 
In the Transwell chemotaxis assay which measures both migration and 
cell response to chemoattractant stimulation, depletion of either rap1 gene 
expression in U373 cells had no effect on their migration toward 2% FBS on 
collagen, fibronectin or vitronectin. This observation is somewhat surprising, 
since one of the well-defined roles of Rap1 is to regulate integrin-dependent 
migration, and the adhesion of rap1b siRNA treated U373 cells to collagen or 
fibronectin coated surface was reduced by 20%. However, when scratch wound 
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healing assay was utilized, I did notice a 20% decrease in the rate of cell 
migration. A possible explanation is that 2% FBS is too strong a chemoattractant 
for U373 cells, as the dose response curve for FBS-stimulated migration of U373 
cells saturates at 0.5% (L. Fan and L.A. Quilliam, Indiana University, unpublished 
observations). 
In line with the reduced invasiveness, U373 cells transfected with rap1b 
siRNA exhibited noticeable elongation in their morphologies. This is consistent 
with a report that malignant glioblastoma cells possess shorter cellular processes 
(176). Along with the morphological change, Rac activity was much higher in the 
rap1b siRNA treated cells. However, whether this is a secondary effect from the 
extensive cytoskeleton rearrangement, or a cause of the extrusion of long cellular 
processes, needs to be determined. 
 
3.2. Rap1 antagonizes multiple signaling pathways in glioblastoma cells 
The role of Rap1 in intracellular signal transduction is highly cell type-
specific. It has been shown that Rap1 could act both upstream and downstream 
of Akt, depending on the cell type (8, 9, 177). Rap1 could promote ERK1/2 
phosphorylation through its effector B-Raf. But in cells that do not express B-Raf, 
Rap1 competes strongly with Ras for c-Raf-1, and negatively regulates ERK. In 
U373 cells, depletion of rap1 by siRNA increased ERK1/2 phosphorylation. It is 
reported that astrocytes do not express B-Raf (129). Therefore, in glioblastoma 
cells that originate from astrocytes, Rap1 could exert an antagonistic role on 
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ERK1/2 by sequestering c-Raf-1. In addition, I have found that in U373 cells, 
ERK could potentiate the phosphorylation of Akt, p38 and S6. However, the 
patterns of action are different for each protein. 
ERK1/2 activation by Rap1 depletion increased Akt phosphorylation in 
both the basal and 2% FBS stimulated conditions. When an ERK1/2 inhibitor, 
U0126, was used, Akt phosphorylation was abrogated in the stimulated condition, 
with or without different siRNA treatment. This suggests that Akt phosphorylation 
is dependent on ERK activity in U373 cells. While most reports show an 
antagonistic relationship between the Raf/MAPK and PI3K/Akt pathways, it has 
also been suggested that ERK could act upstream of Akt to promote its 
activation. PD98059, another ERK inhibitor, inhibited EGTA induced Akt 
phosphorylation in lung epithelial cells (178). U0126 treatment abolished 
ischemia induced Akt phosphorylation in primary rat astrocytes (179). Baudhuin 
and Xu et al. have further identified that in ovarian cancer cells, LPA induced Akt 
phosphorylation at sites S473 and T308 necessary for Akt activation is mediated 
by ERK. They have also shown that ERK promotes the phosphorylation of S473 
on Akt through p38 (133). Based on these findings, it is very likely that in U373 
glioblastoma cells, ERK mediates Akt phosphorylation via both PDK2 and p38. 
p38 was activated by 2% FBS stimulation in U373 cells. This activation 
was further potentiated by the loss of Rap1 in cells. However, when the ERK 
inhibitor U0126 was used, this hyper-activation was corrected. p38 has been 
shown to be phosphorylated by ERK1/2 downstream of oncogenic Ras (180), 
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and in response to LPA for Akt activation (133). On the other hand, LPA- and 
S1P-induced glioma cell migration was inhibited by a p38 inhibitor, but not an 
ERK inhibitor, indicating an ERK-independent p38 activation downstream of LPA 
receptor (181). These findings are supportive of the possible co-existence of 
ERK-independent and ERK-dependent pathways that activate p38 in U373 cells. 
ERK1/2 can act on S6K via RSK or more indirectly through mTOR to 
promote S6 phosphorylation (182, 183). It is therefore not surprising that in 
conditions where ERK1/2 phosphorylation levels were increased by Rap1 
depletion, S6 phosphorylation was also up-regulated. However, when ERK1/2 
activation was blocked with a MEK1/2 inhibitor, rap1 siRNA treatment also 
reduced S6 phosphorylation in response to serum stimulation. This suggests a 
Rap1-dependent regulatory pathway on S6 activation. Forced expression of 
Rap1GAP in WRT thyroid cells impaired TSH/cAMP induced S6 kinase activity 
(184). In mouse macrophages, siRNA silencing of Epac1 drastically reduced the 
activation level of S6 kinase (12). It is suggestive that Rap1 activation in 
response to intracellular cAMP could induce S6 activation in U373 cells. It is clear 
that multiple pathways co-exist in U373 cells that regulate S6 phosphorylation. 
Rap1 could exert both positive and negative effects on S6. My data suggest that 
the inhibitory effect of Rap1 on S6 activate through antagonizing ERK is 
predominant in U373 cells, since the overall effect upon Rap1 knockdown was 
elevated S6 phosphorylation in response to serum stimulation. However, it is also 
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possible that these two opposing pathways are utilized under distinct conditions 
to promote diverse cellular response to environmental changes. 
There was also a small but statistically significant increase in proliferation 
after U373 cells were depleted of Rap1a or Rap1b (Figure D-2). This is likely a 
result of increased ERK1/2, Akt and S6 activation levels, which are tightly 
associated with cell proliferation. However, despite their accelerated growth rate, 
these tumor cells had reduced invasion. This is indicative of an inverse 
relationship between glioblastoma proliferation and invasion. It has been reported 
that overexpression of certain proteins leads to an invasive tumor phenotype but 
with lower proliferation in some tumor types, such as the expression of Rap1GAP 
in squamous cell carcinoma (123), the expression of CCN3 in Ewing?s sarcoma 
(185), and the amplified EphB/R-Ras pathway in glioblastoma (186). In invasive 
gliomas, migrating cells in contact with extracellular matrix have a lower 
proliferation rate when compared with cells in the relative center of a colony, and 
this observation might account for the resistance of invasive gliomas to 
chemotherapies, as chemotherapeutic agents usually target cell proliferation 
(187). My observation that U373 cells depleted of Rap1 are less invasive but 
more proliferative is consistent with this notion. This also agrees with the findings 
of others that Rap1b expression level is higher in more invasive gliomas (111). 
This finding will assist us in understanding the balance between tumor invasion 
and proliferation, and benefit the design of better therapeutic plans for cancer 
treatment. 
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3.3. The differential roles of Rap1a and Rap1b in regulating glioblastoma 
cell invasion and biology 
The data from U373 invasion suggest that the two closely related family 
members, Rap1a and Rap1b, have distinct roles in regulating glioblastoma cell 
behavior. This is in contrast to my findings in Chapter 2 where Rap1a and Rap1b 
mediate the same endothelial cell functions. Others have also observed similar 
phenomena that Rap1a and 1b may have differential roles in epithelial cells. In 
human colonic epithelial cells, knocking down rap1a dramatically impaired 
epithelial monolayer wound healing, and reduced ?1 integrin expression, while 
rap1b knockdown did not have such effects (27). In lung carcinoma cell line 
A549, siRNA depletion of rap1b reduced E-cadherin expression, while rap1a 
knockdown impaired adherens junction maturation (26). No Rap1 GEF, GAP or 
effector has been identified to discriminate between Rap1a versus Rap1b 
binding. The question then is, whether their differential roles observed were due 
to differences in expression levels or different cellular compartmentalization. In 
these two studies, a total Rap1 antibody was used to measure Rap1 level after 
rap1a or rap1b siRNA treatment. This method does not provide a precise 
measurement of the specificity and effectiveness of each siRNA. However, given 
the fact that distinct cellular outcomes were observed, these siRNAs were less 
likely to have cross-reactions. If we assume that the siRNAs were specific for 
each Rap1 family members, then the expression levels of Rap1a and Rap1b 
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were not significantly different in the cell types used in the above two studies. In 
our case, by using a pan-Rap1 antibody combined with a Rap1b-specific 
antiserum, the total Rap1 in endothelial cells was constituted of 40% Rap1a and 
60% Rap1b. This distribution is similarly observed in glioblastoma U373 cells 
(Figure 3-1B). Therefore, the distinct roles of Rap1a and Rap1b are more likely to 
be due to different localizations of the two proteins in the cell. 
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FUTURE DIRECTIONS 
In the first chapter, we have observed multiple embryonic cardiac 
abnormalities in our rap1a knockout mice, including defects in the ventricular 
walls and interventricular septa. If the embryos bearing such defects develop into 
viable pups as I proposed, then the histological analysis and echocardiogram of 
hearts from adult mice should also reveal structural cardiac defects to various 
degrees, in addition to the gross manifestation of cardiac hypertrophy at age of 9 
months or older. It will be interesting to determine the approximate onset timing 
of gross cardiac pathology, to help us determine how big a risk factor loss of 
rap1a gene is. For people who suffer from pathological cardiac hypertrophy, their 
risk of having heart failure and sudden death increase dramatically. However, we 
have not found any of our rap1a knockout mice to die from heart failure under 
normal conditions. As heart failure is usually induced by environmental, physical 
or mental stress, challenging the rap1a null mice of various ages with strenuous 
exercise or high fat diet will reveal how well they endure stress conditions. 
There is also an endothelial cell defect of the rap1a knockout mice that 
contributes to a much dampened angiogenic response to FGF2. However, the 
whole body knockout of rap1a does not allow for a precise dissection of the role 
endothelial cells play during this process. In addition, given the fact that the rap1a 
and rap1b knockout mice both give similar phenotypes during angiogenesis, it is 
reasonable to ask what will happen when the two Rap1 family members are 
silenced simultaneously. However, the rap1a/rap1b double knockout mouse was 
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embryonic lethal, precluding any study of adult mice. Recently, we have acquired 
a rap1a and rap1b conditional knockout mouse from Dr. Morozov. By crossing 
this mouse with mice that express Cre recombinase specifically in endothelial 
cells (such as Tie-2-Cre), we could generate mice that only express trace amount 
of Rap1 in endothelial cells. The use of this model system will enable us to more 
specifically study how loss of Rap1 in endothelial cells impacts mouse 
physiology. It will also be of interest to examine the response of rap1a knockout 
mice in renal or hind limb ischemia models, assays that have a more 
physiological relevance to human diseases. 
Knocking down rap1b seemed to reduce glioblastoma cell malignancy by 
decreasing its invasive properties. It will be beneficial for our understanding to 
inject U373 cells that stably express rap1 shRNAs into the cranial cavity of nude 
mice. We should expect to see a less invasive behavior of the tumor in the 
absence of Rap1b expression. Glioblastomas are also highly angiogenic. Will 
silencing rap1b in glioblastoma also reduce its angiogenic potential? A way to 
test this is to co-culture U373 cells depleted of rap1 and human endothelial cells 
on Matrigel in minimal medium, and examine the ability of the endothelial cells to 
form tubule structures induced by the tumor cells. To validate the in vitro data, 
again, U373 cells stably expressing rap1 shRNAs will be injected into wild type or 
rap1a null mice that have been irradiated to remove their immune system. Will 
we observe a less invasive and less angiogenic tumor in the cohort where rap1b 
shRNA expressing U373 cells are implanted in the rap1a null mice? There are 
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considerations, however, in choosing the glioblastoma cell line for the in vivo 
study. It is now accepted that the established cell lines, despite their origin as 
brain tumors, have lost some of the characteristics of a primary glioblastoma, 
such as EGFR amplification, and quite often behave distinctly from primary 
tumors in xenograft models (188). Researchers in the Mayo Clinic have 
developed and maintained a new panel of human primary glioblastoma cells by 
serial heterotopic transplantation in NOD/SCID immunodeficient mice. These 
cells may be more appropriate for studies that closely resemble the nature of 
primary human tumors. 
Throughout my graduate study, there has remained one key unanswered 
question: What is the relationship between the two Rap1 family members, Rap1a 
and Rap1b? Many data suggest that they are not functionally redundant, 
however, the exact mechanisms are not yet understood. If it is due to different 
intracellular localizations, then transfection of fluorescence tagged Rap1a and 
Rap1b into cells should reveal distinct patterns of distribution of the two proteins. 
A candidate cell type to test will be epithelial cells, as others have observed 
differential roles of Rap1a versus Rap1b in various epithelial cell lines (26, 27). It 
is very likely that multiple pathways exist in the cell to regulate Rap1a and Rap1b 
differently in response to diverse extracellular stimuli, and one mechanism cannot 
explain all the phenomena we have seen. I cannot exclude the possibility that 
Rap1a and Rap1b form dimers to activate downstream effectors. It is shown that 
c-Raf-1 and B-Raf heterodimer has the highest kinase activity (189), and Ras 
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dimerization is required for its activation of Raf (156). Is it possible that Rap1a, 
Rap1b, c-Raf-1 and B-Raf form tetramers in the cell for the full activation of the 
Raf kinase? As was discussed earlier, the dimerization or oligomerization of 
small GTPases is highly dependent on the lipid moiety or salt concentrations. 
Therefore, a more careful study with better-optimized conditions is needed to 
reveal if this proposed model exist in cells. 
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Figure 1-1. Mouse embryonic fibroblast and macrophage adhesion to 
various surfaces. (A) Immortalized MEFs were plated on tissue culture treated, 
5 μg/mL fibronectin or 10 μg/mL rat-tail collagen I coated 96-well plates for 30 
minutes. n=8. (B) Freshly isolated mouse bone marrow-derived macrophages 
were plated on tissue culture treated or 20 μg/mL fibronectin coated 96-well 
plates for 60 minutes. n=5. Adherent cells in (A) and (B) were quantitated by 
staining with crystal violet and measuring absorbance at 600 nm. Bar shows 
mean ± SD. *: p<0.05; ***: p<0.001. 
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Figure 1-2. rap1a-/- mice suffered from embryonic edema. Wild type and 
rap1a-/- embryos of E 14.5 days were dissected and photographed by H. Chen 
and W. Shou. Arrow: edema in the rap1a null embryo.
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Figure 1-3. rap1a-/- embryos manifested various developmental cardiac 
defects. Hearts from wild type and rap1a-/- embryos of E 14.5 and E 18.5 days 
were dissected and examined by H. Chen and W. Shou. Arrows: interventricular 
septa defects; arrow heads: ventricular wall defects. 
Wild type                                 rap1a-/- 
E 14.5 
E 18.5 
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Figure 1-4. rap1a-/- mice had higher heart-to-body weight ratio than wild 
type mice. The total body and dissected heart from age matched (9 month or 
older) wild type and rap1a-/- mice were weighed, and heart-to-total body weight 
ratios were calculated (WT 5.29±0.19 vs. KO 6.09±0.72). Wild type n= 8; rap1a-/- 
n=15. Bar shows mean ± SD. **: p<0.01. 
** 
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Figure 2-1. VEGF alone did not strongly induce angiogenesis in mouse 
Matrigel plug assay. Matrigel containing either PBS or VEGF of designated 
concentration was injected subcutaneously into wild type and rap1a-/- mice. The 
Matrigel plugs were recovered at day 7 and hemoglobin content reflecting new 
blood vessel formation was measured. Bar shows mean ± SE, n=10 for PBS 
group; n=4 for 600 ng/mL VEGF group and n=3 for 150 ng/mL VEGF group. 
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Figure 2-2. rap1a knockout mouse had impaired angiogenic response to 
FGF2. (A) Matrigel plugs containing 20 U/mL heparin plus either PBS or 600 
ng/mL FGF2 were injected subcutaneously into wild type and rap1a-/- mice. Left 
panel, the Matrigel plugs were recovered at day 7 and images were taken. Right 
panel, hemoglobin content of recovered Matrigel plugs, reflecting new blood 
A 
B 
PBS              FGF2 
WT 
rap1a-/- 
Wild type                                          rap1a-/- 
*** 
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vessel formation. Bar shows mean ± SE, ***: p<0.001, n=8. (B) Endothelial cells 
migrated into Matrigel plugs were revealed by CD31 staining. Images are 
representative of experiments from 5 mice of each genotype. 
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Figure 2-3. rap1a null mouse aortic rings had impaired tube outgrowth in 
response to FGF2. (A) Aortic rings of 1 mm thickness from either wild type or 
rap1a-/- mice were embedded in Matrigel supplemented with 20 U/mL heparin, 
2% FBS, with or without 25 ng/mL FGF2. The outgrowth of aortic tubes was 
observed at day 7 and representative images are shown. (B) Quantification of 
aortic tube outgrowth and branching. Bar shows mean ± SD, ***: p<0.001, n=5. 
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Figure 2-4. siRNAs selectively knocked down endogenous Rap1a or Rap1b 
expression in human micro-vascular endothelial cells (HMVECs) and 
exogenous Rap1a or Rap1b in 293T cells. (A) Upper panel, endogenous total 
Rap1, Rap1b and GAPDH levels in HMVECs; Middle panel, densitometric 
quantification of protein level in cells. Bar shows mean ± SD, n=3; Bottom panel, 
GST-Rap1a and HA-Rap1b levels in 293T cells. (B) Total Rap1 level and 
GAPDH from additional set of siRNAs. 
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Figure 2-5. Knock down of Rap1 expression increased HMVEC junction 
permeability. HMVECs transfected with control, rap1a, rap1b, or rap1a plus 
rap1b siRNAs were plated on 0.4 ?m filters and cultured until confluent. 
Transendothelial resistance (TER) was measured as an indicator of endothelial 
monolayer integrity. Bar shows mean ± SD, ***: p<0.001, n=8. 
*** *** 
*** 
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Figure 2-6. Suppressing Rap1 expression decreased HMVEC chemotaxis to 
FGF2 and wound-healing migration. (A) HMVECs transfected with control, 
rap1a, rap1b, or rap1a plus rap1b siRNAs were plated on 10 μg/mL collagen 
coated 8 ?m Transwell filters. Cells were allowed to migrate toward 60 nM FGF2 
for 6 hours. Cell numbers in 3 random high magnification fields were averaged 
and normalized. Bar shows mean ± SD, *: p<0.05, n=4. (B) HMVECs transfected 
with two distinct sets of siRNAs were cultured until confluent. Representative 
data is shown for set I. Cells were removed in one direction by a razor blade and 
a small incision was made in the plastic to mark the starting point of migration. 
Distance migrated was recorded after 24 hr. Filled arrows indicate the start point 
of migration; open arrows indicate end point of migration. Scale bar=100 μm. (C) 
Quantification of cell migration. Bar shows mean ± SD, ***: p<0.001, n=3. 
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Figure 2-7. Suppressing Rap1 expression decreased HMVEC adhesion to 
extracellular matrix proteins. HMVECs transfected with different siRNAs (set I) 
were plated on type I collagen or fibronectin matrices in 96-well plates for 30 
minutes. Adherent cells were quantitated by staining with Crystal Violet and 
measuring absorbance at 600 nm. Bar shows mean ± SD, ***: p<0.001 vs 
control, #: p<0.05 vs Rap1a and Rap1b, n=4. 
*** *** 
*** # 
*** *** 
*** # 
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Figure 2-8. Loss of Rap1 decreased HMVEC proliferation. HMVECs 
transfected with control, rap1a, rap1b, or rap1a plus rap1b siRNAs were cultured 
for 72 hr in EBM-2 with different concentrations of FGF2 as indicated. Cell 
proliferation was measured and expressed as fold increase in absorbance versus 
control. *: p<0.05 on siRNA control versus rap1 siRNA treated cells, n=3. 
* 
* 
* 
* 
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Figure 2-9. Reducing Rap1 expression abolished HMVEC tube formation on 
Matrigel. HMVECs transfected with two distinct sets of control, rap1a, rap1b, or 
rap1a plus rap1b siRNAs were plated on Matrigel in vitro in the presence of 25 
ng/mL FGF2 and tubular structures allowed to develop for 12 hr. (A) 
Representative images of HMVEC tube formation. Scale bar=500 μm. (B) 
Quantification of total tube length. Bar shows mean ± SD, ***: p<0.001, n=3. 
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Figure 2-10. Rap1 was activated by FGF2 in endothelial cells. (A) HMVECs 
were starved overnight and stimulated with 25 ng/mL FGF2 for 3-60 min. 
Immunoblots for Rap1-GTP and total Rap1 level were performed. (B) 
Densitometric quantification of protein levels. Bars show mean ± SD, *: p<0.05, 
n=3. (C) Endogenous total FGFR-1 and GAPDH levels in HMVECs.
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Figure 2-11. Rap1 depletion abolished Rac activation in HMVECs. (A) 
HMVECs transfected with control, rap1a, rap1b, or rap1a plus rap1b siRNAs 
were starved overnight and stimulated with 25 ng/mL FGF2 and 10 μg/mL 
heparin for 10 minutes. Immunoblots for Rac-GTP and total Rac level were 
performed. (B) Densitometric quantification of protein levels. Bars show mean ± 
SD, **: p<0.01 vs control, #: p<0.05 vs Rap1a and Rap1b, n=4. 
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** ** 
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Figure 2-12. Rap1 mediated ERK1/2 activation by FGF2 in HMVECs. (A) 
HMVECs were starved overnight and stimulated with 25 ng/mL FGF2 for 3-60 
min. Immunoblots for phosphorylated ERK1/2 and total ERK1/2 are shown. (B) 
HMVECs transfected with control, rap1a, rap1b, or rap1a plus rap1b siRNAs 
were starved overnight and incubated ± 25 ng/mL FGF2 for 10 min. Immunoblots 
for phosphorylated and total ERK1/2 are shown. (C) Densitometric quantification 
of protein levels. Bars show mean ± SD, *: p<0.05, n=3. 
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Figure 2-13. Rap1 did not mediate ERK1/2 activation by VEGF in HMVECs. 
HMVECs transfected with control, rap1a, rap1b, or rap1a plus rap1b siRNAs 
were starved overnight and incubated ± 25 ng/mL VEGF for 10 min. Immunoblots 
representative of 2 independent experiments for phosphorylated and total 
ERK1/2 are shown.
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Figure 2-14. Rap1 mediated p38 activation by FGF2 in HMVECs. (A) 
HMVECs were starved overnight and stimulated with 25 ng/mL FGF2 for 3-60 
min. Immunoblots for phosphorylated p38 and total p38 are shown. (B) HMVECs 
transfected with control, rap1a, rap1b, or rap1a plus rap1b siRNAs were starved 
overnight and incubated ± 25 ng/mL FGF2 for 10 min. Immunoblots for 
phosphorylated and total p38 are shown. (C) Densitometric quantification of 
protein levels. Bars show mean ± SD, *: p<0.05, n=3. 
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Figure 2-15. FGF2 did not mediate Pyk2 activation in HMVECs. HMVECs 
were starved overnight and stimulated with 25 ng/mL FGF2 for 3-60 minutes. 
Immunoblots representative of 2 independent experiments for phosphorylated 
Pyk2 and total Pyk2 are shown. 
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Figure 3-1. Loss of Rap1b induced morphological changes in U373 
glioblastoma cells. U373 cells were transfected with control, rap1a or rap1b 
siRNAs. (A) Upper panel, representative images of U373 cell morphology after 
siRNA transfection, scale bar=48 μm; Lower panel, enlargement of 
representative single cell morphology, scale bar=28 μm. (B) Upper left panel, 
relative expression levels of Rap1a and Rap1b in U373 cells; Upper right panel, 
Rac-GTP and total Rac levels; Lower panel, densitometric quantification of Rac-
GTP levels. Bars show mean ± SD, **: p<0.01, n=5. 
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Figure 3-2. rap1 shRNAs induced similar morphological changes in U373 
cells. U373 cells were infected with lentiviruses encoding various rap1 shRNAs. 
(A) Immunoblots of Rap1-GTP, total Rap1, Rap1b-GTP, total Rap1b and GAPDH 
following virus infection are shown. (B) Representative images of U373 cells 
following virus infection are shown. 
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Figure 3-3. Rap1b depletion reduced glioblastoma cell invasion in vitro. 
U373 cells transfected with various siRNAs were placed on 8 μm Transwell filters 
coated with a thin layer of Matrigel, and allowed to invade toward 10% FBS. 
Representative photographs from 4 independent experiments are shown. 
siControl                        siRap1a                         siRap1b 
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Figure 3-4. Loss of Rap1 decreased the activity of secreted MMP2 in U373 
cells. (A) Conditioned media from U373 cells transfected with various siRNAs 
were collected for MMP zymography assay. (B) Densitometric quantification of 
MMP2 activity. Bars show mean ± SD, *: p<0.05 vs control, #: p<0.05 vs Rap1a, 
n=3. 
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Figure 3-5. Suppressing Rap1b expression decreased U373 adhesion to 
collagen and fibronectin, but not to vitronectin. U373 cells transfected with 
different siRNAs were plated on type I collagen, fibronectin, or vitronectin 
matrices in 96-well plates for 60 minutes. Adherent cells were quantitated by 
staining with Crystal Violet and measuring absorbance at 600 nm. Bar shows 
mean ± SD, **: p<0.005, n=3. 
** ** 
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Figure 3-6. FBS and EGF stimulation activated Rap1 in U373 cells. (A) U373 
cells starved overnight were stimulated with 10% FBS, 15 ng/mL PDGF, 15 
ng/mL FGF2 or 30 ng/mL EGF for the time courses as indicated. Immunoblots for 
Rap1-GTP and total Rap1 are shown. (B) U373 cells starved overnight were 
stimulated with 15 ng/mL EGF for the time courses as indicated or with 10% FBS 
for 10 minutes. Immunoblots for Rap1-GTP and total Rap1 are shown. 
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Figure 3-7. U373 cell chemotaxis to FBS was not affected by rap1 
knockdown. (A) U373 cells were plated on 10 ng/mL collagen coated 8 μm 
Transwell filters and allowed to migrate toward media containing 0.1% FBS, 10% 
FBS or 15 ng/mL EGF. Representative images from 2 independent experiments 
are shown. (B) U373 cells transfected with control, rap1a or rap1b siRNAs were 
plated on various matrix proteins coated Transwell filters as indicated, and 
allowed to migrate toward 2% FBS. Representative images from 2 independent 
experiments are shown. 
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Figure 3-8. U373 cell wound-healing migration was decreased by rap1 
depletion. (A) U373 cells transfected with various siRNAs were cultured until 
confluent. Cells were removed in one direction by a razor blade and a small 
incision was made in the plastic to mark the starting point of migration. Images 
shown are after 24 hours of migration. (B) Quantification of cell migration. Bar 
shows mean ± SD, *: p<0.05, n=3. 
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Figure 3-9. Suppression of Rap1 expression increased Akt, ERK, S6 and 
p38 phosphorylation stimulated by 2% FBS. (A) U373 cells transfected with 
various siRNAs were starved overnight before stimulated with 10% FBS for 10 
minutes. Immunoblots for phosphorylated and total Akt and ERK1/2 are shown. 
(B) U373 cells transfected with various siRNAs were starved overnight before 
stimulated with 2% FBS for 10 minutes. Immunoblots for phosphorylated and 
total Akt, ERK1/2, S6 and p38 are shown. (C) Densitometric quantification of 
protein levels. Bars show mean ± SD, *: p<0.05, **: p<0.01, n=3.
114 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-10. ERK inhibition decreased Akt, S6 and p38 phosphorylation 
induced by Rap1 depletion. U373 cells were transfected with various siRNAs 
and starved overnight. Cells were pre-treated with 10 μM U0126 for 30 minutes 
before stimulated with 2% FBS for 10 minutes. Immunoblots for phosphorylated 
and total Akt, S6, p38 and ERK1/2 are shown. 
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Figure D-1. Rap1b expression levels were elevated in rap1a null 
neutrophils. Wild type and rap1a null neutrophils were isolated and blotted for 
Rap1b protein level. Two out of 3 rap1a null neutrophil samples had elevated 
Rap1b expression. 
Rap1b 
 
GAPDH 
Wild type rap1a-/- 
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Figure D-2. Rap1b depletion increased glioblastoma cell proliferation. U373 
cells transfected with control, rap1a, or rap1b siRNAs were cultured for 72 hr in 
RPMI-1640 with different concentrations of FBS as indicated. Cell proliferation 
was measured and expressed as fold increase in absorbance versus control. *: 
p<0.05 versus control siRNA treated cells, n=2.
* 
* * * 
* 
* 
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